Publications

2023

Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges.

Mountzios G, Remon J, Hendriks LEL, García-Campelo R, Rolfo C, Van Schil P, Forde PM, Besse B, Subbiah V, Reck M, Soria JC, Peters S

Nat Rev Clin Oncol. 2023 Oct;20(10):664-677

A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.

Bobisse S, Bianchi V, Tanyi JL, Sarivalasis A, Missiaglia E, Pétremand R, Benedetti F, Torigian DA, Genolet R, Barras D, Michel A, Mastroyannis SA, Zsiros E, Dangaj Laniti D, Tsourti Z, Stevenson BJ, Iseli C, Levine BL, Speiser DE, Gfeller D, Bassani-Ster

Nat Cancer. 2023 Sep 21

Elevated liver function tests in a patient with breast cancer.

Neftel C, Zaman K, Chtioui H, Moradpour D, Sempoux C, Fraga M

J Hepatol. 2023 Sep;79(3):e109-e111

European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.

Opitz I, Bille A, Dafni U, Nackaerts K, Ampollini L, de Perrot M, Brcic L, Nadal E, Syrigos K, Gray SG, Aerts J, Curioni-Fontecedro A, Rüschoff JH, Monkhorst K, Weynand B, Silini EM, Bavaghar-Zaeimi F, Jakopovic M, Llatjos R, Tsimpoukis S, Finn SP, von de

J Thorac Oncol. 2023 Sep;18(9):1233-1247

Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.

Cathomas R, Rothschild SI, Hayoz S, Bubendorf L, Özdemir BC, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel RT, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U

J Clin Oncol. 2023 Aug 17:JCO2300363

Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.

Templeton AJ, Omlin A, Berthold D, Beyer J, Burger IA, Eberli D, Engeler D, Fankhauser C, Fischer S, Gillessen S, Nicolas G, Kroeze S, Lorch A, Müntener M, Papachristofilou A, Schaefer N, Seiler D, Stenner F, Tsantoulis P, Vlajnic T, Zilli T, Zwahlen D, C

Swiss Med Wkly. 2023 Aug 15;153:40108

(99m)Tc-macroaggregated albumin SPECT/CT predictive dosimetry and dose-response relationship in uveal melanoma liver metastases treated with first-line selective internal radiation therapy.

Tabotta F, Gnesin S, Dunet V, Ponti A, Digklia A, Boughdad S, Schaefer N, Prior JO, Villard N, Tsoumakidou G, Denys A, Duran R

Sci Rep. 2023 Aug 12;13(1):13118

Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.

Kristeleit R, Leary A, Delord JP, Moreno V, Oaknin A, Castellano D, Shappiro GI, Fernández C, Kahatt C, Alfaro V, Siguero M, Rueda D, Zeaiter A, Awada A, Santaballa A, Zaman K, Sehouli J, Subbiah V

Invest New Drugs. 2023 Aug 9

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.

Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, Cortinovis D, Le AT, Huang D, Liu G, Cappuzzo F, Reyes Contreras J, Reck M, Palmero R, Mak MP, Hu Y, Morris S, Höglander E, Connors M, Biggane AM, V

Lancet. 2023 Aug 5;402(10400):451-463

Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.

Reck M, Ciuleanu TE, Lee JS, Schenker M, Zurawski B, Kim SW, Mahave M, Alexandru A, Peters S, Pluzanski A, Caro RB, Linardou H, Burgers JA, Nishio M, Martinez-Marti A, Azuma K, Axelrod R, Paz-Ares LG, Ramalingam SS, Borghaei H, O'Byrne KJ, Li L, Bushong J

J Thorac Oncol. 2023 Aug;18(8):1055-1069

Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.

Passaro A, Mok TSK, Attili I, Wu YL, Tsuboi M, de Marinis F, Peters S

JAMA Oncol. 2023 Aug 1;9(8):1124-1131

Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.

Passaro A, Jänne PA, Peters S

J Clin Oncol. 2023 Jul 20;41(21):3747-3761

The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies.

Sun X, Abrahamson P, Ballew N, Kalilani L, Phiri K, Bell KF, Slowley A, Zajac M, Hofstatter E, Stojadinovic A, Silvestro A, Wang Z, Aziez A, Peters S

Cancer Invest. 2023 Jul;41(6):571-592

Optimal Delivery of Follow-Up Care Following Treatment for Adults Treated for Ewing Sarcoma.

Digklia A, Dolcan A, Kucharczyk MA, Jones RL, Napolitano A

Cancer Manag Res. 2023;15:537-545

Cytokine storm complicated by cardiogenic shock induced by anti-HER2 therapies.

Godinho R, Noto A, Fenwick C, Stravodimou A, Hugelshofer S, Peters S, Hullin R, Obeid M

J Immunother Cancer. 2023 Jun;11(6)

Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.

Goldschmid H, Kluck K, Ball M, Kirchner M, Allgäuer M, Winter H, Herth F, Heußel CP, Pullamsetti SS, Savai R, Yong TTK, Schirmacher P, Peters S, Thomas M, Christopoulos P, Budczies J, Stenzinger A, Kazdal D

Lung Cancer. 2023 Jun;180:107212

Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature.

Liapi A, Atat C, Dunet V, Sarivalasis A

SAGE Open Med Case Rep. 2023;11:2050313X231176401

[Salivary gland cancer: new therapeutic approaches].

Herrera Gomez RG, Mederos N, Szturz P, Degrauwe N, Jankovic J, Cristina V

Rev Med Suisse. 2023 May 17;19(827):958-963

[Prostate cancer in the era of precision medicine: a new horizon].

Nguyen-Ngoc T, Berthold D, Normand C

Rev Med Suisse. 2023 May 17;19(827):950-956

Carrières en oncologie et leadership féminin : les progrès sont-ils au point mort ?

Peters S, Addeo A, Aapro M

Rev Med Suisse. 2023 May 17;19(827):929-930

[Endometrial cancer in the crossroads of modernity and immunotherapy].

Giacomuzzi Moore B, Liapi A, Dolcan A, Kakourou A, Masmoudi S, Latifyan S, Sarivalasis A

Rev Med Suisse. 2023 May 17;19(827):944-949

Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance.

Hwang M, Chia YL, Zheng Y, Chen CC, He J, Song X, Zhou D, Goldberg SB, Siu LL, Planchard D, Peters S, Mann H, Krug L, Even C

Br J Clin Pharmacol. 2023 May;89(5):1601-1616

Immunotherapy-based combinations in metastatic NSCLC.

Desai A, Peters S

Cancer Treat Rev. 2023 May;116:102545

Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives.

Kris MG, Mitsudomi T, Peters S

Transl Lung Cancer Res. 2023 Apr 28;12(4):824-836

Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I/II study.

Cloitre M, Valerio M, Mampuya A, Rakauskas A, Berthold D, Tawadros T, Meuwly JY, Heym L, Duclos F, Vallet V, Zeverino M, Jichlinski P, Prior J, Roth B, Bourhis J, Herrera FG

Br J Radiol. 2023 Apr 1;96(1145):20220803

A neutrophil response linked to tumor control in immunotherapy.

Gungabeesoon J, Gort-Freitas NA, Kiss M, Bolli E, Messemaker M, Siwicki M, Hicham M, Bill R, Koch P, Cianciaruso C, Duval F, Pfirschke C, Mazzola M, Peters S, Homicsko K, Garris C, Weissleder R, Klein AM, Pittet MJ

Cell. 2023 Mar 30;186(7):1448-1464.e20

A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.

Mamot C, Wicki A, Hasler-Strub U, Riniker S, Li Q, Holer L, Bärtschi D, Zaman K, von Moos R, Dedes KJ, Boos LA, Novak U, Bodmer A, Ritschard R, Obermann EC, Tzankov A, Ackermann C, Membrez-Antonioli V, Zürrer-Härdi U, Caspar CB, Deuster S, Senn M, Winterh

Sci Rep. 2023 Mar 6;13(1):3705

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial.

de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Fer

Lancet. 2023 Mar 4;401(10378):733-746

The Landscape and Therapeutic Targeting of BRCA1, BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer.

Voutsadakis IA, Digklia A

Curr Issues Mol Biol. 2023 Mar 3;45(3):2105-2120

Clear cell sarcoma: state-of-the art and perspectives.

Wetterwald L, Riggi N, Kyriazoglou A, Dei Tos G, Dei Tos A, Digklia A

Expert Rev Anticancer Ther. 2023 Mar;23(3):235-242

Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies.

Voutsadakis IA, Stravodimou A

Anticancer Res. 2023 Mar;43(3):967-981

Imaging assessment of toxicity related to immune checkpoint inhibitors.

Berz AM, Boughdad S, Vietti-Violi N, Digklia A, Dromain C, Dunet V, Duran R

Front Immunol. 2023;14:1133207

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.

Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Shi X, Poole L, Peters S, Garon EB, Mok T, POSEIDON investigators

J Clin Oncol. 2023 Feb 20;41(6):1213-1227

Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy.

Mastelic-Gavillet B, Sarivalasis A, Lozano LE, Lofek S, Wyss T, Melero I, de Vries IJM, Harari A, Romero P, Kandalaft LE, Viganó S

Front Immunol. 2023;14:1119371

Lung stereotactic radiation therapy: Intercomparison of irradiation devices in terms of outcome and predictive factors.

Le Reun E, Casutt A, Durham A, Bouchaab H, Romano E, Lovis A, Krueger T, Von Garnier C, Özsahin EM, Kinj R

Cancer Radiother. 2023 Feb;27(1):31-41

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.

Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B

J Thorac Oncol. 2023 Feb;18(2):181-193

Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.

Voutsadakis IA, Digklia A

Chin Clin Oncol. 2023 Feb;12(1):2

Lymph Node Involvement in Recurrent Serous Borderline Ovarian Tumors: Current Evidence, Controversies, and a Review of the Literature.

Wetterwald L, Sarivalasis A, Liapi A, Mathevet P, Achtari C

Cancers (Basel). 2023 Jan 31;15(3)

[Oncology: what's new in 2022].

Nguyen-Ngoc T, Abdelhamid K, Degrauwe N, Galland S, Serena A, Christofis M, Mederos N, Bouchaab H, Diciolla A, Dris N, Orcurto A, Perrinjaquet C, Schnetz M, Latifyan S, Wetterwald L, Herrera Gómez RG, Cristina V, Sarivalasis A, Michielin O, Berthold D, Di

Rev Med Suisse. 2023 Jan 18;19(N° 809-10):52-57

Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study.

Bandiera C, Locatelli I, Courlet P, Cardoso E, Zaman K, Stravodimou A, Dolcan A, Sarivalasis A, Zurcher JP, Aedo-Lopez V, Dotta-Celio J, Peters S, Guidi M, Wagner AD, Csajka C, Schneider MP

Cancers (Basel). 2023 Jan 3;15(1)

Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial.

Peters S, Letovanec I, Mauer M, Dafni U, Ejedepang D, Biernat W, Bubendorf L, Warth A, Pokharel S, Reinmuth N, Majem Tarruella M, Casas-Martin J, Tsourti Z, Marti N, Kammler R, Danson S, O'Brien M, Stahel RA

Lung Cancer. 2023 Jan;175:141-151

Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma.

Haber PK, Castet F, Torres-Martin M, Andreu-Oller C, Puigvehí M, Miho M, Radu P, Dufour JF, Verslype C, Zimpel C, Marquardt JU, Galle PR, Vogel A, Bathon M, Meyer T, Labgaa I, Digklia A, Roberts LR, Mohamed Ali MA, Mínguez B, Citterio D, Mazzaferro V, Fin

Gastroenterology. 2023 Jan;164(1):72-88.e18

Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.

Paz-Ares LG, Ciuleanu TE, Pluzanski A, Lee JS, Gainor JF, Otterson GA, Audigier-Valette C, Ready N, Schenker M, Linardou H, Caro RB, Provencio M, Zurawski B, Lee KH, Kim SW, Caserta C, Ramalingam SS, Spigel DR, Brahmer JR, Reck M, O'Byrne KJ, Girard N, Po

J Thorac Oncol. 2023 Jan;18(1):79-92

Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].

Hasler-Strub U, Mueller A, Li Q, Thuerlimann B, Ribi K, Gerber S, von Moos R, Fehr M, Rochlitz C, Zaman K, Aebi S, Hochstrasser A, Gick U, Baertschi D, Greuter S, Schreiber A, Caspar CB, Trojan A, Condorelli R, Ruhstaller T, Swiss Group for Clinical Cance

J Geriatr Oncol. 2023 Jan;14(1):101372

2022

A differential process mining analysis of COVID-19 management for cancer patients.

Cuendet MA, Gatta R, Wicky A, Gerard CL, Dalla-Vale M, Tavazzi E, Michielin G, Delyon J, Ferahta N, Cesbron J, Lofek S, Huber A, Jankovic J, Demicheli R, Bouchaab H, Digklia A, Obeid M, Peters S, Eicher M, Pradervand S, Michielin O

Front Oncol. 2022;12:1043675

Correction to: Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project.

Rüschoff JH, Haberecker M, Tsourti Z, Nackaerts K, de Perrot M, Brcic L, Nadal E, Tsimpoukis S, Gray SG, Ampollini L, Aerts JG, Felley-Bosco E, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, von der Thü

Mod Pathol. 2022 Dec;35(12):2033

Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer.

Aapro M, Cardoso F, Curigliano G, Eniu A, Gligorov J, Harbeck N, Mueller A, Pagani O, Paluch-Shimon S, Senkus E, Thürlimann B, Zaman K

Breast. 2022 Dec;66:145-156

Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort.

Bubendorf L, Zoche M, Dafni U, Rüschoff JH, Prince SS, Marti N, Stavrou A, Kammler R, Finn SP, Moch H, Peters S, Stahel RA

Lung Cancer. 2022 Dec;174:27-35

Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project.

Mod Pathol. 2022 Dec;35(12):1888-1899

Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.

Furrer K, Weder W, Eboulet EI, Betticher D, Pless M, Stupp R, Krueger T, Perentes JY, Schmid RA, Lardinois D, Furrer M, Früh M, Peters S, Curioni-Fontecedro A, Stahel RA, Rothschild SI, Hayoz S, Opitz I

J Thorac Cardiovasc Surg. 2022 Dec;164(6):1587-1602.e5

Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.

Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen V, Bartsch R, Cortes J, P

Cancer Treat Rev. 2022 Dec;111:102468

Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries.

Cortellini A, Dettorre GM, Dafni U, Aguilar-Company J, Castelo-Branco L, Lambertini M, Gennatas S, Angelis V, Sita-Lumsden A, Rogado J, Pedrazzoli P, Viñal D, Prat A, Rossi M, Berardi R, Alonso-Gordoa T, Grisanti S, Dimopoulou G, Queirolo P, Pradervand S,

J Immunother Cancer. 2022 Nov;10(11)

Patients' experiences with cancer care in Switzerland: Results of a multicentre cross-sectional survey.

Arditi C, Eicher M, Colomer-Lahiguera S, Bienvenu C, Anchisi S, Betticher D, Dietrich PY, Duchosal M, Peters S, Peytremann-Bridevaux I

Eur J Cancer Care (Engl). 2022 Nov;31(6):e13705

Minus Times Minus Equals Plus.

Haanen J, Peters S

J Clin Oncol. 2022 Oct 10;40(29):3453-3455

Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events.

Coukos A, Vionnet J, Obeid M, Bouchaab H, Peters S, Latifyan S, Wicky A, Michielin O, Chtioui H, Moradpour D, Fasquelle F, Sempoux C, Fraga M

J Immunother Cancer. 2022 Oct;10(10)

Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.

Felip E, Smit EF, Molina-Vila MA, Dafni U, Massuti B, Berghmans T, de Marinis F, Passiglia F, Dingemans AC, Cobo M, Viteri S, Britschgi C, Cuffe S, Provencio M, Merkelbach-Bruse S, Andriakopoulou C, Kammler R, Ruepp B, Roschitzki-Voser H, Peters S, Wolf J

Lung Cancer. 2022 Oct;172:94-99

First communication on the efficacy of combined (177)Lutetium-PSMA with immunotherapy outside prostate cancer.

Digklia A, Boughdad S, Homicsko K, Dromain C, Trimech M, Dolcan A, Peters S, Prior J, Schaefer N

J Immunother Cancer. 2022 Oct;10(10)

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.

Davis EJ, Martin-Liberal J, Kristeleit R, Cho DC, Blagden SP, Berthold D, Cardin DB, Vieito M, Miller RE, Hari Dass P, Orcurto A, Spencer K, Janik JE, Clark J, Condamine T, Pulini J, Chen X, Mehnert JM

J Immunother Cancer. 2022 Oct;10(10)

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.

O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Samkari A, Keller SM, Mauer M, Jha N, Stahel R, Besse B, Peters S, EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYN

Lancet Oncol. 2022 Oct;23(10):1274-1286

Organoids: A New Chapter in Sarcoma Diagnosis and Treatment.

Psilopatis I, Kokkali S, Palamaris K, Digklia A, Vrettou K, Theocharis S

Int J Mol Sci. 2022 Sep 24;23(19)

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).

Ascierto PA, Agarwala SS, Blank C, Caracò C, Carvajal RD, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, Grob JJ, Hamid O, Krogsgaard M, Lo RS, Lund AW, Madonna G, Michielin O, Neyns B, Osman I, Peters S, Poulikakos PI, Quezada SA, Reinfeld B, Zitv

J Transl Med. 2022 Sep 4;20(1):391

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.

Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS,

Nat Med. 2022 Sep;28(9):1831-1839

Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin.

Adamina M, Warlaumont M, Berger MD, Däster S, Delaloye R, Digklia A, Gloor B, Fritsch R, Koeberle D, Koessler T, Lehmann K, Müller P, Peterli R, Ris F, Steffen T, Weisshaupt CS, Hübner M

Cancers (Basel). 2022 Sep 1;14(17)

An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves.

Wysocki O, Zhou C, Rogado J, Huddar P, Shotton R, Tivey A, Albiges L, Angelakas A, Arnold D, Aung T, Banfill K, Baxter M, Barlesi F, Bayle A, Besse B, Bhogal T, Boyce H, Britton F, Calles A, Castelo-Branco L, Copson E, Croitoru A, Dani SS, Dickens E, East

Cancers (Basel). 2022 Aug 16;14(16)

Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.

Hibar DP, Demetri GD, Peters S, Davies J, Humblet O, Maund SL, Perez L

PLoS One. 2022;17(8):e0270571

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).

James ND, Clarke NW, Cook A, Ali A, Hoyle AP, Attard G, Brawley CD, Chowdhury S, Cross WR, Dearnaley DP, de Bono JS, Diaz-Montana C, Gilbert D, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Matheson DJ, Millman R, Parker CC, Pugh C, Rush H, Russe

Int J Cancer. 2022 Aug 1;151(3):422-434

Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis.

Bestvina CM, Whisenant JG, Torri V, Cortellini A, Wakelee H, Peters S, Roca E, De Toma A, Hirsch FR, Mamdani H, Halmos B, Arrieta O, Metivier AC, Fidler MJ, Rogado J, Presley CJ, Mascaux C, Genova C, Blaquier JB, Addeo A, Finocchiaro G, Khan H, Mazieres J

JTO Clin Res Rep. 2022 Aug;3(8):100335

Inflammatory Myofibroblastic Tumour: State of the Art.

Gros L, Dei Tos AP, Jones RL, Digklia A

Cancers (Basel). 2022 Jul 27;14(15)

Setting the Benchmark for KRAS(G12C) -Mutated NSCLC.

Passaro A, Peters S

N Engl J Med. 2022 Jul 14;387(2):180-183

A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.

Banna GL, Addeo A, Zygoura P, Tsourti Z, Popat S, Curioni-Fontecedro A, Nadal E, Shah R, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Janthur WD, López-Castro R, Roschitzki-Voser H, Dafni U, Peters S, Stahel RA

Lung Cancer. 2022 Jul;169:77-83

Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.

Peters S, Paz-Ares L, Herbst RS, Reck M

J Immunother Cancer. 2022 Jul;10(7)

[Occupational cancers: essentials for the general practioners].

Krief P, Cohidon C, Turcu V, Rinaldo M, Kamara M, Koller M, Zyska Cherix A, Senn N, Peters S

Rev Med Suisse. 2022 Jun 29;18(788):1313-1321

Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer.

Courlet P, Cardoso E, Bandiera C, Stravodimou A, Zurcher JP, Chtioui H, Locatelli I, Decosterd LA, Darnaud L, Blanchet B, Alexandre J, Wagner AD, Zaman K, Schneider MP, Guidi M, Csajka C

Pharmaceutics. 2022 Jun 21;14(7)

Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor.

Scabia V, Ayyanan A, De Martino F, Agnoletto A, Battista L, Laszlo C, Treboux A, Zaman K, Stravodimou A, Jallut D, Fiche M, Bucher P, Ambrosini G, Sflomos G, Brisken C

Nat Commun. 2022 Jun 6;13(1):3127

[Targeted therapies and non-small cell carcinomas : novelties].

Stauber R, Gro S L, Nguyen-Ngoc T, Mederos N, Bouchaab H, Peters S, Abdelhamid K

Rev Med Suisse. 2022 May 18;18(782):970-975

[Intraperitoneal therapy for carcinomatosis in ovarian cancer: proposed treatment algorithm].

Undurraga M, Mathevet P, Hubner M, Buchs NC, Warlaumont M, Sarivalasis A, Diciolla A, Lang N, Koessler T, Digklia A, Ris F, Petignat P, Labidi-Galy I

Rev Med Suisse. 2022 May 18;18(782):990-996

[Adverse effects of new breast cancer therapies : when to react ?].

Dris N, Meyer ML, Flores Torres C, Curtit E, Zurcher JP, Stravodimou A, Zaman K

Rev Med Suisse. 2022 May 18;18(782):997-1001

Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.

Dziadziuszko R, Peters S, Mok T, Camidge DR, Gadgeel SM, Ou SI, Konopa K, Noé J, Nowicka M, Bordogna W, Morcos PN, Smoljanovic V, Shaw AT

Clin Cancer Res. 2022 May 2;28(9):1800-1808

Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer.

Digklia A, Coukos G, Homicsko K

Clin Cancer Res. 2022 May 2;28(9):1745-1747

First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.

Scherpereel A, Antonia S, Bautista Y, Grossi F, Kowalski D, Zalcman G, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Sun X, Lawrance R, Zhang X, Daumont MJ, Bennett B, McKenna M, Baas P

Lung Cancer. 2022 May;167:8-16

Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.

Lee RJ, Wysocki O, Zhou C, Shotton R, Tivey A, Lever L, Woodcock J, Albiges L, Angelakas A, Arnold D, Aung T, Banfill K, Baxter M, Barlesi F, Bayle A, Besse B, Bhogal T, Boyce H, Britton F, Calles A, Castelo-Branco L, Copson E, Croitoru AE, Dani SS, Dicke

JCO Clin Cancer Inform. 2022 May;6:e2100177

A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.

Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Monnet I, Boudjemaa A, Rogado J, Pasello G, Leighl NB, Arrieta O, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez

J Thorac Oncol. 2022 May;17(5):661-674

CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small

De Ruysscher D, Ramalingam S, Urbanic J, Gerber DE, Tan DSW, Cai J, Li A, Peters S

Clin Lung Cancer. 2022 May;23(3):e264-e268

Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.

Obeid M, Suffiotti M, Pellaton C, Bouchaab H, Cairoli A, Salvadé V, Stevenel C, Hottinger R, Pythoud C, Coutechier L, Molinari L, Trono D, Ribi C, Gottardo R, Fenwick C, Pascual M, Duchosal MA, Peters S, Pantaleo G

JAMA Oncol. 2022 May 1;8(5):e220446

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E

Lancet. 2022 Apr 30;399(10336):1695-1707

Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer.

Mulvey A, Muggeo-Bertin E, Berthold DR, Herrera FG

Front Immunol. 2022;13:859785

Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report.

Ball M, Christopoulos P, Kirchner M, Allgäuer M, Brandt R, Winter H, Heußel CP, Herth F, Fröhling S, Savai R, Kriegsmann M, Schirmacher P, Peters S, Thomas M, Stenzinger A, Kazdal D

Cold Spring Harb Mol Case Stud. 2022 Apr;8(3)

EWSR1-ATF1 dependent 3D connectivity regulates oncogenic and differentiation programs in Clear Cell Sarcoma.

Möller E, Praz V, Rajendran S, Dong R, Cauderay A, Xing YH, Lee L, Fusco C, Broye LC, Cironi L, Iyer S, Rengarajan S, Awad ME, Naigles B, Letovanec I, Ormas N, Finzi G, La Rosa S, Sessa F, Chebib I, Petur Nielsen G, Digklia A, Spentzos D, Cote GM, Choy E,

Nat Commun. 2022 Apr 27;13(1):2267

Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).

Joerger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt AM, Cantoni N, Caspar CB, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz JD, Kopp C, Hayoz S, Stathis A, von Moos R, Swiss Group for Clinical Cancer Research

Cancers (Basel). 2022 Apr 27;14(9)

Delayed Diagnosis of Lung Carcinoma Presenting as Choroidal Metastasis in a COVID-19 Patient and Initially Treated with Osimertinib.

Haeller CN, Khamsy L, Kloepper J, Schiappacasse L, Bouchaab H, Peters S, Schalenbourg A

Klin Monbl Augenheilkd. 2022 Apr;239(4):586-589

Efficacy of Eribulin in Soft Tissue Sarcomas.

Phillips E, Jones RL, Huang P, Digklia A

Front Pharmacol. 2022;13:869754

Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients.

Papadopoulos S, Koulouris P, Royer-Chardon C, Tsoumakidou G, Dolcan A, Cherix S, Matter M, Omoumi P, Digklia A

Front Endocrinol (Lausanne). 2022;13:794512

Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis.

Tan AC, Tan SH, Zhou S, Peters S, Curigliano G, Tan DSW

Cancer Treat Rev. 2022 Mar;104:102354

Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma.

Aedo-Lopez V, Gérard CL, Boughdad S, Gautron Moura B, Berthod G, Digklia A, Homicsko K, Schaefer N, Duran R, Cuendet MA, Michielin O

Cancers (Basel). 2022 Feb 24;14(5)

Neurotrophic receptor tyrosine kinase family members in secretory and non-secretory breast carcinomas.

Stravodimou A, Voutsadakis IA

World J Clin Oncol. 2022 Feb 24;13(2):135-146

Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.

Passaro A, Brahmer J, Antonia S, Mok T, Peters S

J Clin Oncol. 2022 Feb 20;40(6):598-610

[2021 Oncology update].

Meyer ML, Chrysou K, Stamatiou A, Gilabert M, Herrera Gomez RG, Latifyan S, Masmoudi S, Mederos N, Perrinjaquet C, Berthold D, Bouchaab H, Cristina V, Digklia A, Michielin O, Orcurto A, Sarivalasis A, Stravodimou A, Wagner AD, Zaman K, Peters S, Jankovic

Rev Med Suisse. 2022 Feb 2;18(767):182-186

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.

Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgäuer M, Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Goldmann T, Fröhling S, Wermke M, Waller CF, Tufman A, Reck M, Peters S, Schirmacher P, Thomas M, Christopoulos P, Stenzinger

Cancer Immunol Immunother. 2022 Feb;71(2):251-265

Immunotherapy for Esophageal Cancer: State-of-the Art in 2021.

Teixeira Farinha H, Digklia A, Schizas D, Demartines N, Schäfer M, Mantziari S

Cancers (Basel). 2022 Jan 22;14(3)

Targeting HER2-Mutant NSCLC - The Light Is On.

Passaro A, Peters S

N Engl J Med. 2022 Jan 20;386(3):286-289

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).

Peters S, Galle PR, Bernaards CA, Ballinger M, Bruno R, Quarmby V, Ruppel J, Vilimovskij A, Wu B, Sternheim N, Reck M

Clin Transl Sci. 2022 Jan;15(1):141-157

Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.

Michielin O, Lalani AK, Robert C, Sharma P, Peters S

J Immunother Cancer. 2022 Jan;10(1)

Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.

Herrera FG, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M, Corria-Osorio J, Spill A, Benedetti F, Genolet R, Orcurto A, Imbimbo M, Ghisoni E, Navarro Rodrigo B, Berthold DR, Sarivalasis A, Zaman K, Duran R, Dromain C, Prior J, Schaefer N, Bour

Cancer Discov. 2022 Jan;12(1):108-133

2021

So-Called Serous Carcinoma of the Uterine Cervix with BRCA2 Mutation: Case Report and Review of the Literature.

Herrera Gómez RG, Hastir D, Liapi A, Dolcan A, Herrera FG, Mathevet P, Sarivalasis A

Case Rep Oncol. 2021 Sep-Dec;14(3):1792-1798

Case Report: Vasculitis Triggered by SIRT in a Patient With Previously Untreated Cholangiocarcinoma.

Stamatiou A, Jankovic J, Szturz P, Fasquelle F, Duran R, Schaefer N, Diciolla A, Digklia A

Front Oncol. 2021;11:755750

[Cancer center clinical nurse: The experience of the CHUV Prostate Cancer Center].

Codeluppi C, Ninane F, Jolliet L, Glemarec P, Orcurto A, Rakauskas A, Tawadros T, Bosshard P, Eicher M, Herrera F, La Rosa S, Meuwly JY, Vietti-Violi N, Prior J, Schaefer N, Bessaire B, Ehrensperger M, Roth B, Berthold D, Valerio M

Rev Med Suisse. 2021 Dec 1;17(761):2082-2085

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort.

Dziadziuszko R, Mok T, Peters S, Han JY, Alatorre-Alexander J, Leighl N, Sriuranpong V, Pérol M, de Castro Junior G, Nadal E, de Marinis F, Frontera OA, Tan DSW, Lee DH, Kim HR, Yan M, Riehl T, Schleifman E, Paul SM, Mocci S, Patel R, Assaf ZJ, Shames DS,

J Thorac Oncol. 2021 Dec;16(12):2040-2050

COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response.

Desai A, Mohammed TJ, Duma N, Garassino MC, Hicks LK, Kuderer NM, Lyman GH, Mishra S, Pinato DJ, Rini BI, Peters S, Warner JL, Whisenant JG, Wood WA, Thompson MA

JAMA Oncol. 2021 Dec 1;7(12):1882-1890

Early discharge after thoracoscopic anatomical pulmonary resection for non-small-cell lung cancer.

Forster C, Perentes JY, Ojanguren A, Abdelnour-Berchtold E, Zellweger M, Bouchaab H, Peters S, Krueger T, Gonzalez M

Interact Cardiovasc Thorac Surg. 2021 Nov 22;33(6):892-898

A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma.

Harari A, Sarivalasis A, de Jonge K, Thierry AC, Huber F, Boudousquie C, Rossier L, Orcurto A, Imbimbo M, Baumgaertner P, Bassani-Sternberg M, Kandalaft LE

Cancers (Basel). 2021 Nov 18;13(22)

Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials.

Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe HS, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Barneto Aranda I, Scherz A, Tsourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, O'Brien M

Lung Cancer. 2021 Nov;161:76-85

Pilot Testing of a Nurse-Led Basic Symptom Self-management Support for Patients Receiving First-Line Systemic Outpatient Anticancer Treatment: A Cluster-Randomized Study (Symptom Navi Pilot Study).

Bana M, Ribi K, Peters S, Kropf-Staub S, Näf E, Zürcher-Florin S, Stoffel B, Blaeuer C, Borner M, Malin D, Biber R, Betticher D, Kuhn-Bächler T, Cantoni N, Seeger T, Bütikofer L, Eicher M, Symptom Navi Program Group

Cancer Nurs. 2021 Nov-Dec 01;44(6):E687-E702

Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC.

Vuong D, Bogowicz M, Wee L, Riesterer O, Vlaskou Badra E, D'Cruz LA, Balermpas P, van Timmeren JE, Burgermeister S, Dekker A, De Ruysscher D, Unkelbach J, Thierstein S, Eboulet EI, Peters S, Pless M, Guckenberger M, Tanadini-Lang S

Sci Rep. 2021 Oct 22;11(1):20890

Is sleeve lobectomy safe after induction therapy?-a systematic review and meta-analysis.

Chriqui LE, Forster C, Lovis A, Bouchaab H, Krueger T, Perentes JY, Gonzalez M

J Thorac Dis. 2021 Oct;13(10):5887-5898

(68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis.

Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ, Salem JE, Schaefer N, Nicod-Lalonde M, Costes J, Perreau M, Michielin O, Peters S, Prior JO, Obeid M

J Immunother Cancer. 2021 Oct;9(10)

The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19.

Li A, Kuderer NM, Hsu CY, Shyr Y, Warner JL, Shah DP, Kumar V, Shah S, Kulkarni AA, Fu J, Gulati S, Zon RL, Li M, Desai A, Egan PC, Bakouny Z, Kc D, Hwang C, Akpan IJ, McKay RR, Girard J, Schmidt AL, Halmos B, Thompson MA, Patel JM, Pennell NA, Peters S,

J Thromb Haemost. 2021 Oct;19(10):2522-2532

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.

Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, Mauti LA, Britschgi C, Weder W, Peters S, Mark M, Cathomas R, Ochsenbein AF, Janthur WD, Waibel C, Mach N, Froesch P, Buess M, Bohane

J Clin Oncol. 2021 Sep 10;39(26):2872-2880

Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human.

Chiang CL, Rovelli R, Sarivalasis A, Kandalaft LE

Cancers (Basel). 2021 Sep 10;13(18)

Papillary Thyroid Carcinoma with Desmoid-Type Fibromatosis: Review of Published Cases.

Roukain A, La Rosa S, Bongiovanni M, Nicod Lalonde M, Cristina V, Montemurro M, Cochet S, Luquain A, Kopp PA, Sykiotis GP

Cancers (Basel). 2021 Sep 6;13(17)

Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer.

Schettini F, Giuliano M, Lambertini M, Bartsch R, Pinato DJ, Onesti CE, Harbeck N, Lüftner D, Rottey S, van Dam PA, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen VCG, Cortes J, Locci M, Paris I, Del Mastro L, De

Cancers (Basel). 2021 Sep 1;13(17)

Imaging Features of Pulmonary Immune-related Adverse Events.

Pozzessere C, Lazor R, Jumeau R, Peters S, Prior JO, Beigelman-Aubry C

J Thorac Oncol. 2021 Sep;16(9):1449-1460

Swiss germ-cell cancer consensus recommendations.

Beyer J, Berthold D, Bode PK, Cathomas R, Fankhauser CD, Fischer S, Gillessen S, Gross T, Hermanns T, Honecker F, Lorch A, Omlin A, Papachristofilou A, Roth B, Rothermundt C, Seiler R, Spahn M, Stenner F, Bührer E

Swiss Med Wkly. 2021 Aug 23;151(33-34)

Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging.

Oliveira C, Amstutz F, Vuong D, Bogowicz M, Hüllner M, Foerster R, Basler L, Schröder C, Eboulet EI, Pless M, Thierstein S, Peters S, Hillinger S, Tanadini-Lang S, Guckenberger M

EJNMMI Res. 2021 Aug 21;11(1):79

Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study.

Rakauskas A, Tawadros T, Lucca I, Herrera F, Bourhis J, Burruni R, Gomes MN, Codeluppi C, Jolliet L, La Rosa S, Meuwly JY, Jichlinski P, Berthold D, Valerio M

Investig Clin Urol. 2021 Jul;62(4):416-422

Neutrophils in the era of immune checkpoint blockade.

Faget J, Peters S, Quantin X, Meylan E, Bonnefoy N

J Immunother Cancer. 2021 Jul;9(7)

Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).

Garon EB, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, Robinet G, Le Moulec S, Natale R, Schneider J, Shepherd FA, Garassino MC, Geater SL, Szekely ZP, Van Ngoc T, Liu F, Scheuring U, Patel N, Peters S, Rizvi NA

Clin Lung Cancer. 2021 Jul;22(4):301-312.e8

Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data.

Bandiera C, Cardoso E, Locatelli I, Digklia A, Zaman K, Diciolla A, Cristina V, Stravodimou A, Veronica AL, Dolcan A, Sarivalasis A, Liapi A, Bouchaab H, Orcurto A, Dotta-Celio J, Peters S, Decosterd L, Widmer N, Wagner D, Csajka C, Schneider MP

JMIR Res Protoc. 2021 Jun 29;10(6):e30090

Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases.

Gros L, Szturz P, Diciolla A, Kirchner V, Peters S, Schaefer N, Hubner M, Digklia A

Front Oncol. 2021;11:704295

[Management of abdominal soft tissue sarcomas].

Djafarrian R, Zingg T, Digklia A, Becce F, Özsahin EM, La Rosa S, Demartines N, Matter M

Rev Med Suisse. 2021 Jun 16;17(743):1172-1176

A new method to visualize and to spare the ureters during SBRT for oligo metastatic patients.

Muggeo-Bertin E, Moeckli R, Vallet V, Berthold D, Godin S, Bourhis J, Herrera FG

Tech Innov Patient Support Radiat Oncol. 2021 Sep;19:7-10

[New-onset diabetes and novel targeted therapies against cancer].

Zordan A, Kosinski C, Zaman K, Wojtusciszyn A

Rev Med Suisse. 2021 Jun 2;17(741):1067-1071

Treatment Decisions for Patients with Cancer during the COVID-19 Pandemic.

Labaki C, Peters S, Choueiri TK

Cancer Discov. 2021 Jun;11(6):1330-1335

Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression.

Tavernari D, Battistello E, Dheilly E, Petruzzella AS, Mina M, Sordet-Dessimoz J, Peters S, Krueger T, Gfeller D, Riggi N, Oricchio E, Letovanec I, Ciriello G

Cancer Discov. 2021 Jun;11(6):1490-1507

Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.

Finn SP, Addeo A, Dafni U, Thunnissen E, Bubendorf L, Madsen LB, Biernat W, Verbeken E, Hernandez-Losa J, Marchetti A, Cheney R, Warth A, Speel EM, Quinn AM, Monkhorst K, Jantus-Lewintre E, Tischler V, Marti N, Dimopoulou G, Molina-Vila MA, Kammler R, Ker

J Thorac Oncol. 2021 Jun;16(6):990-1002

Invasive Breast Cancer in a Trans Man After Bilateral Mastectomy: Case Report and Literature Review.

Kopetti C, Schaffer C, Zaman K, Liapi A, di Summa PG, Bauquis O

Clin Breast Cancer. 2021 Jun;21(3):e154-e157

Chemotherapy and targeted treatments of breast sarcoma by histologic subtype.

Kokkali S, Stravodimou A, Duran-Moreno J, Koufopoulos N, Voutsadakis IA, Digklia A

Expert Rev Anticancer Ther. 2021 Jun;21(6):591-604

Oncologie et pandémie de Covid-19 : les patients au cœur des enjeux.

Dietrich PY, Aapro M, Peters S

Rev Med Suisse. 2021 May 19;17(739):955

[Immunotherapy for bladder cancer in 2021].

Cisarovsky C, Latifyan S, Perrinjaquet C, Berthold D, Orcurto A

Rev Med Suisse. 2021 May 19;17(739):974-977

[Breast cancer during pregnancy].

Schnetz M, Stravodimou A, Cisarovsky C, Dunand A, Prior JO, Nicod Lalonde M, Baud D, Meuwly JY, Winterfeld U, Zaman K

Rev Med Suisse. 2021 May 19;17(739):957-961

[Anaplastic thyroid carcinoma : new therapeutic approaches].

Stamatiou A, Herrera-Gómez RG, Szturz P, Bisig B, Romano E, Sykiotis G, Gorostidi F, La Rosa S, Kopp P, Cristina V

Rev Med Suisse. 2021 May 19;17(739):962-966

Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.

Passaro A, Mok T, Peters S, Popat S, Ahn MJ, de Marinis F

J Thorac Oncol. 2021 May;16(5):764-773

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.

Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, Gérard CL, Latifyan S, Özdemir BC, Caikovski M, Pradervand S, Tavazzi E, Gatta R, Marandino L, Valabrega G, Aglietta M, Obeid M, Homicsko K, Mederos Alfonso NN, Zimmermann S, Coukos G,

Eur J Cancer. 2021 May;149:153-164

GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy.

Ancey PB, Contat C, Boivin G, Sabatino S, Pascual J, Zangger N, Perentes JY, Peters S, Abel ED, Kirsch DG, Rathmell JC, Vozenin MC, Meylan E

Cancer Res. 2021 May 1;81(9):2345-2357

Cell therapies in ovarian cancer.

Sarivalasis A, Morotti M, Mulvey A, Imbimbo M, Coukos G

Ther Adv Med Oncol. 2021;13:17588359211008399

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.

Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, Dakhil SR, Navarro A, Rodríguez-Cid J, Schenker M, Lee JS, Gutierrez V, Percent I, Morgensztern D, Barrios CH, Greillier L, Baka S, Patel M, Lin WH, Selvaggi G, Baudelet C, Baden J, Pandya D, Do

J Clin Oncol. 2021 Apr 20;39(12):1349-1359

[Telephone follow-up of SARS-CoV-2 positive patients at the Oncology Department of Lausanne University Hospital].

Jankovic J, Da Silva Lopes AM, Morez A, Darnac C, Demicheli R, Dalla-Vale M, Lauriers N, Garcia Sanchez J, Bouchaab H, Ninane F, Peters S, Michielin O, Pradervand S, Eicher M, Colomer-Lahiguera S

Rev Med Suisse. 2021 Apr 7;17(733):703-707

Stereotactic lung reirradiation for local relapse: A case series.

Kinj R, Casutt A, Bennassi A, Bouchaab H, Vallet V, Lovis A, Ozsahin M

Clin Transl Radiat Oncol. 2021 May;28:85-87

Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma.

Kazdal D, Rempel E, Oliveira C, Allgäuer M, Harms A, Singer K, Kohlwes E, Ormanns S, Fink L, Kriegsmann J, Leichsenring M, Kriegsmann K, Stögbauer F, Tavernar L, Leichsenring J, Volckmar AL, Longuespée R, Winter H, Eichhorn M, Heußel CP, Herth F, Christop

Transl Lung Cancer Res. 2021 Apr;10(4):1666-1678

The Promising Evolution of Targeted Therapeutic Strategies in Cancer.

Peters S, Mok T, Passaro A, Jänne PA

Cancer Discov. 2021 Apr;11(4):810-814

OncoAlert Round Table Discussions: The Global COVID-19 Experience.

Morgan G, de Azambuja E, Punie K, Ades F, Heinrich K, Personeni N, Rahme R, Ferrara R, Pels K, Garassino M, von Bergwelt-Baildon M, Lopes G, Barlesi F, Choueiri TK, Burris H, Peters S

JCO Glob Oncol. 2021 Apr;7:455-463

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.

Piccart M, van 't Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis PA, Causeret S, Smilde TJ, Viale G, Glas AM, Delorenzi M, Sotiriou C, Rubio IT, Kümmel S, Zoppoli G, Thompson AM, Matos E, Za

Lancet Oncol. 2021 Apr;22(4):476-488

Overcoming therapy resistance in EGFR-mutant lung cancer.

Passaro A, Jänne PA, Mok T, Peters S

Nat Cancer. 2021 Apr;2(4):377-391

Expert Discussion: Immunotherapy in Breast Cancer - Ready for Prime Time?

Rinnerthaler G, Müller V, Balic M, Zaman K, Dieci MV

Breast Care (Basel). 2021 Apr;16(2):188-191

VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature.

Liapi A, Mathevet P, Herrera FG, Hastir D, Sarivalasis A

Front Oncol. 2021;11:641376

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.

Si H, Kuziora M, Quinn KJ, Helman E, Ye J, Liu F, Scheuring U, Peters S, Rizvi NA, Brohawn PZ, Ranade K, Higgs BW, Banks KC, Chand VK, Raja R

Clin Cancer Res. 2021 Mar 15;27(6):1631-1640

Intraductal xenografts show lobular carcinoma cells rely on their own extracellular matrix and LOXL1.

Sflomos G, Battista L, Aouad P, De Martino F, Scabia V, Stravodimou A, Ayyanan A, Ifticene-Treboux A, RLS, Bucher P, Fiche M, Ambrosini G, Brisken C

EMBO Mol Med. 2021 Mar 5;13(3):e13180

Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.

Gandara D, Reck M, Moro-Sibilot D, Mazieres J, Gadgeel S, Morris S, Cardona A, Mendus D, Ballinger M, Rittmeyer A, Peters S

J Immunother Cancer. 2021 Mar;9(3)

Severity of COVID-19 in patients with lung cancer: evidence and challenges.

Passaro A, Bestvina C, Velez Velez M, Garassino MC, Garon E, Peters S

J Immunother Cancer. 2021 Mar;9(3)

Strength in numbers: predicting response to checkpoint inhibitors from large clinical datasets.

Stenzinger A, Kazdal D, Peters S

Cell. 2021 Feb 4;184(3):571-573

Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.

Mok T, Peters S, Camidge DR, Noé J, Gadgeel S, Ou SI, Kim DW, Konopa K, Pozzi E, Liu T, Loftin IR, Williams C, Shaw AT

J Thorac Oncol. 2021 Feb;16(2):259-268

Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platf

Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Álvarez R, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Lambrecht M, Andratschke N, Tsourti Z, Piguet AC, Roschitzki-Voser H, Gasca-Ruchti A, Vansteenkiste J, Stahel RA, De Ruysscher D

J Thorac Oncol. 2021 Feb;16(2):278-288

Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.

Moi L, Bouchaab H, Mederos N, Nguyen-Ngoc T, Perreau M, Fenwick C, Vaucher J, Sempoux C, Peters S, Obeid M

J Thorac Oncol. 2021 Feb;16(2):318-326

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G

Lancet. 2021 Jan 30;397(10272):375-386

[2020 oncology update].

Dei Tos G, Galli Vareia I, Huber A, Wolf B, Diciolla A, Herrera Gomez RG, Wagner D, Digklia A, Bouchaab H, Cristina V, Stravodimou A, Zaman K, Sarivalasis A, Berthold D, Peters S, Perrinjaquet C, Kloepper J, Jankovic J

Rev Med Suisse. 2021 Jan 27;17(723):201-205

A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma.

Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgäuer M, Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Fröhling S, Peters S, Seliger B, Schirmacher P, Thomas M, Christopoulos P, Stenzinger A

Oncoimmunology. 2021 Jan 11;10(1):1860586

Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab.

Mampuya WA, Bouchaab H, Schaefer N, Kinj R, La Rosa S, Letovanec I, Ozsahin M, Bourhis J, Coukos G, Peters S, Herrera FG

Clin Transl Radiat Oncol. 2021 Mar;27:85-88

Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study.

Forster C, Doucet V, Perentes JY, Abdelnour-Berchtold E, Zellweger M, Faouzi M, Bouchaab H, Peters S, Marcucci C, Krueger T, Rosner L, Gonzalez M

Transl Lung Cancer Res. 2021 Jan;10(1):93-103

2020

Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

Le Tourneau C, Tao Y, Gomez-Roca C, Cristina V, Borcoman E, Deutsch E, Bahleda R, Calugaru V, Modesto A, Rouits E, Gollmer K, Vuagniaux G, Crompton P, Zanna C, Szyldergemajn S, Delord JP, Bourhis J

Clin Cancer Res. 2020 Dec 15;26(24):6429-6436

Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.

Burns TF, Borghaei H, Ramalingam SS, Mok TS, Peters S

J Clin Oncol. 2020 Dec 10;38(35):4208-4218

Radiomics Feature Activation Maps as a New Tool for Signature Interpretability.

Vuong D, Tanadini-Lang S, Wu Z, Marks R, Unkelbach J, Hillinger S, Eboulet EI, Thierstein S, Peters S, Pless M, Guckenberger M, Bogowicz M

Front Oncol. 2020;10:578895

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.

Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA, López-Vilariño JA, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Zaman K, López R, Ponce S, Boni V, Arrondeau J, Delord JP, Martínez M, Wannesson L, Antón A, Valdivia J, Awada A, Kriste

Lung Cancer. 2020 Dec;150:90-96

Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians.

Chazan G, Franchini F, Alexander M, Banerjee S, Mileshkin L, Blinman P, Zielinski R, Karikios D, Pavlakis N, Peters S, Lordick F, Ball D, Wright G, I Jzerman M, Solomon B

ESMO Open. 2020 Dec;5(6):e001090

[Lung cancer screening in Switzerland : Who ? How ? When ?].

Casutt A, Lovis A, Selby K, Noirez L, Peters S, Beigelman-Aubry C, Krueger T, Soccal PM, Von Garnier C

Rev Med Suisse. 2020 Nov 18;16(715):2224-2226

The METeoric rise of MET in lung cancer.

Friedlaender A, Drilon A, Banna GL, Peters S, Addeo A

Cancer. 2020 Nov 15;126(22):4826-4837

Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience.

Trama A, Proto C, Whisenant JG, Torri V, Cortellini A, Michielin O, Barlesi F, Dingemans AC, Van Meerbeeck J, Pancaldi V, Mazieres J, Soo RA, Leighl NB, Peters S, Wakelee H, Horn L, Hellmann M, Wong SK, Garassino MC, Baena J

Cancer Cell. 2020 Nov 9;38(5):602-604

Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.

Passaro A, Stenzinger A, Peters S

Cancer Cell. 2020 Nov 9;38(5):624-625

COVID-19 and Cancer: Current Challenges and Perspectives.

Bakouny Z, Hawley JE, Choueiri TK, Peters S, Rini BI, Warner JL, Painter CA

Cancer Cell. 2020 Nov 9;38(5):629-646

[Risk communication in healthcare: literature review and recommendations for clinical practice].

Durand MA, Selby K, Bodenmann P, Zaman K, Ducros C, Cornuz J

Rev Med Suisse. 2020 Nov 4;16(713):2092-2098

[Lung cancer screening: what can we tell our patients while we await a screening program ?].

Selby K, Gubelmann R, Lovis A, Bulliard JL, Beigelman-Aubry C, Casutt A, Peters S, Krueger T, Von Garnier C, Cornuz J

Rev Med Suisse. 2020 Nov 4;16(713):2086-2091

Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer.

Mederos N, Friedlaender A, Peters S, Addeo A

ESMO Open. 2020 Nov;5(Suppl 4):e000796

Transarterial Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma Invading the Right Atrium.

Girardet R, Boughdad S, Digklia A, Beigelman C, Meyer M, Schaefer N, Vermersch M, Hocquelet A, Tsoumakidou G, Denys A, Duran R

Cardiovasc Intervent Radiol. 2020 Nov;43(11):1712-1715

Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX Study.

Mok T, Peters S, Camidge DR, Noé J, Gadgeel S, Ignatius Ou SH, Kim DW, Konopa K, Pozzi E, Liu T, Loftin IR, Williams C, Shaw AT

J Thorac Oncol. 2020 Oct 24

Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma.

Goebell PJ, Ivanyi P, Bedke J, Bergmann L, Berthold D, Boegemann M, Busch J, Doehn C, Krege S, Retz M, Amsberg GV, Grimm MO, Gruenwald V

Future Oncol. 2020 Oct;16(29):2307-2328

Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.

Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu CY, Rubinstein SM, Lee BJ, Choueiri TK, de Lima Lopes G Jr, Grivas P, Painter CA, Rini BI, Thompson MA, Arcobello J, Bakouny Z, Doroshow DB, Egan PC, Farmakiotis D, Fecher LA, Friese CR, Galsky

Cancer Discov. 2020 Oct;10(10):1514-1527

A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOU

Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodriguez-Abreu D, Falchero L, Moran T, Ortega Granados AL, Monnet I, Mohorcic K, Sureda BM, Betticher D, Demedts I, Macias JA, Cuffe S, Luciani A, Sanchez JG

J Thorac Oncol. 2020 Oct;15(10):1647-1656

Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers.

Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Sternberg CN, Bellmunt J, Galsky MD, Harshman LC, RISC Inves

Eur Urol Oncol. 2020 Oct;3(5):671-679

Survival of the fetus: cervical cancer and pregnancy, a challenging combination.

Levy L, Meuwly JY, Sarivalasis A, Achtari C, Mathevet P, Herrera FG

Lancet. 2020 Sep 5;396(10252):725

The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.

Stravodimou A, Voutsadakis IA

Anticancer Res. 2020 Sep;40(9):4829-4841

Comparison of robust to standardized CT radiomics models to predict overall survival for non-small cell lung cancer patients.

Vuong D, Bogowicz M, Denzler S, Oliveira C, Foerster R, Amstutz F, Gabryś HS, Unkelbach J, Hillinger S, Thierstein S, Xyrafas A, Peters S, Pless M, Guckenberger M, Tanadini-Lang S

Med Phys. 2020 Sep;47(9):4045-4053

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.

Sholl LM, Hirsch FR, Hwang D, Botling J, Lopez-Rios F, Bubendorf L, Mino-Kenudson M, Roden AC, Beasley MB, Borczuk A, Brambilla E, Chen G, Chou TY, Chung JH, Cooper WA, Dacic S, Lantuejoul S, Jain D, Lin D, Minami Y, Moreira A, Nicholson AG, Noguchi M, Pa

J Thorac Oncol. 2020 Sep;15(9):1409-1424

Paraneoplastic Cerebellar Ataxia Can Affect Prognosis in High-Grade Serous Ovarian Cancer: A Case Report.

Liapi A, Sarivalasis A

Case Rep Oncol. 2020 May-Aug;13(2):1006-1012

Oncological care organisation during COVID-19 outbreak.

Onesti CE, Rugo HS, Generali D, Peeters M, Zaman K, Wildiers H, Harbeck N, Martin M, Cristofanilli M, Cortes J, Tjan-Heijnen V, Hurvitz SA, Berchem G, Tagliamento M, Campone M, Bartsch R, De Placido S, Puglisi F, Rottey S, Müller V, Ruhstaller T, Machiels

ESMO Open. 2020 Aug;5(4)

Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.

Ürün Y, Hussain SA, Bakouny Z, Castellano D, Kılıçkap S, Morgan G, Mckay RR, Pels K, Schmidt A, Doroshow DB, Schütz F, Albiges L, Lopes G, Catto JWF, Peters S, Choueiri TK

JCO Glob Oncol. 2020 Aug;6:1248-1257

Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.

Schmid S, Mauti LA, Friedlaender A, Blum V, Rothschild SI, Bouchaab H, Frösch P, Britschgi C, König D, Wannesson L, Janthur WD, Schär S, Demmer I, Addeo A, Jochum W, Früh M

Cancer Immunol Immunother. 2020 Aug;69(8):1605-1613

Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.

Mastelic-Gavillet B, Sarivalasis A, Lozano LE, Wyss T, Inoges S, de Vries IJM, Dartiguenave F, Jichlinski P, Derrè L, Coukos G, Melero I, Harari A, Romero P, Viganó S, Kandalaft LE

Eur J Cancer. 2020 Aug;135:173-182

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, Kalemkerian GP, Luo Y, Ebiana V, Pietanza MC, Kim HR, KEYNOTE-604 Investigators

J Clin Oncol. 2020 Jul 20;38(21):2369-2379

Oncology during the COVID-19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients.

Tsamakis K, Gavriatopoulou M, Schizas D, Stravodimou A, Mougkou A, Tsiptsios D, Sioulas V, Spartalis E, Sioulas AD, Tsamakis C, Charalampakis N, Mueller C, Arya D, Zarogoulidis P, Spandidos DA, Dimopoulos MA, Papageorgiou C, Rizos E

Oncol Lett. 2020 Jul;20(1):441-447

Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic.

Dingemans AC, Soo RA, Jazieh AR, Rice SJ, Kim YT, Teo LLS, Warren GW, Xiao SY, Smit EF, Aerts JG, Yoon SH, Veronesi G, De Cobelli F, Ramalingam SS, Garassino MC, Wynes MW, Behera M, Haanen J, Lu S, Peters S, Ahn MJ, Scagliotti GV, Adjei AA, Belani CP

J Thorac Oncol. 2020 Jul;15(7):1119-1136

Gender gap: surveying the world for tomorrow.

Garrido P, Tsang J, Peters S

ESMO Open. 2020 Jul;5(4)

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.

Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, Baena J, Banna G, Berardi R, Bettini AC, Bria E, Brighenti M, Cadranel J, De Toma A, Chini C, Cortellini A, Felip E, Finocchiaro G, Garrido P, Genova C, Giusti R, Gregorc V, Grossi F, Gro

Lancet Oncol. 2020 Jul;21(7):914-922

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA

Lancet. 2020 Jun 20;395(10241):1907-1918

The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer.

Rubinstein SM, Steinharter JA, Warner J, Rini BI, Peters S, Choueiri TK

Cancer Cell. 2020 Jun 8;37(6):738-741

TERAVOLT: Thoracic Cancers International COVID-19 Collaboration.

Whisenant JG, Trama A, Torri V, De Toma A, Viscardi G, Cortellini A, Michielin O, Barlesi F, Dingemans AC, Van Meerbeeck J, Pancaldi V, Soo RA, Leighl NB, Peters S, Wakelee H, Garassino MC, Horn L

Cancer Cell. 2020 Jun 8;37(6):742-745

Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.

Haanen J, Ernstoff M, Wang Y, Menzies A, Puzanov I, Grivas P, Larkin J, Peters S, Thompson J, Obeid M

J Immunother Cancer. 2020 Jun;8(1)

Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.

Peters S, Shaw AT, Besse B, Felip E, Solomon BJ, Soo RA, Bearz A, Gadgeel SM, Lin CC, Kao S, Seto T, Masters ET, Abbattista A, Clancy JS, Thurm H, Reisman A, Peltz G, Ross Camidge D

Lung Cancer. 2020 Jun;144:10-19

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer.

Passaro A, Addeo A, Von Garnier C, Blackhall F, Planchard D, Felip E, Dziadziuszko R, de Marinis F, Reck M, Bouchaab H, Peters S

ESMO Open. 2020 Jun;5(Suppl 3)

Challenges in lung cancer therapy during the COVID-19 pandemic.

Calabrò L, Peters S, Soria JC, Di Giacomo AM, Barlesi F, Covre A, Altomonte M, Vegni V, Gridelli C, Reck M, Rizvi N, Maio M

Lancet Respir Med. 2020 Jun;8(6):542-544

Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis.

Dolladille C, Font J, Bejan-Angoulvant T, Zaman K, Sassier M, Ezine E, Stefan A, Plane AF, Legallois D, Milliez P, Parienti JJ, Alexandre J

Arch Cardiovasc Dis. 2020 Jun-Jul;113(6-7):420-432

Une période de craintes et de défis : vers un monde meilleur ?

Dietrich PY, Aapro M, Peters S

Rev Med Suisse. 2020 May 27;16(695):1071-1072

[Small-cell lung cancer: management and novelties].

Abdelhamid K, Kakourou A, Degrauwe N, Nikolopoulou A, Bouchaab H, Peters S, Nguyen-Ngoc T, Mederos N

Rev Med Suisse. 2020 May 27;16(695):1079-1085

[Breast cancer: perspectives from integrative medicine].

Stravodimou A, Zurron N, Fleury M, Stanic J, Ramos Chapuis M, Eicher M, Berna C, Zaman K

Rev Med Suisse. 2020 May 27;16(695):1102-1105

Describing adverse events in Swiss hospitalized oncology patients using the Global Trigger Tool.

Gerber A, Da Silva Lopes A, Szüts N, Simon M, Ribordy-Baudat V, Ebneter A, Perrinjaquet C, Gaignard ME, Nicodet D, Betticher D, Bula G, Cote M, Duchosal MA, Berret PA, Dietrich PY, Brennan C, Decosterd S, Ferreira Nobre S, Peters S, Koelliker R, Ninane F,

Health Sci Rep. 2020 Jun;3(2):e160

Increased Risk of Multiple Spontaneous Vertebral Fractures at Denosumab Discontinuation Must Be Taken Into Account.

Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, Zaman K, Lamy O

J Clin Oncol. 2020 May 10;38(14):1641-1642

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.

Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anto

Lancet Oncol. 2020 May;21(5):645-654

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.

Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs

JAMA Oncol. 2020 May 1;6(5):661-674

Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungs

Thunnissen E, Kerr KM, Dafni U, Bubendorf L, Finn SP, Soltermann A, Biernat W, Cheney R, Verbeken E, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Tsourti Z, Geiger T, Kammler R, Peters S, Stahel RA, European Tho

Mod Pathol. 2020 May;33(5):792-801

[Oncology: navigating the COVID-19 Pandemic and Steer the Course].

Zimmermann S, Dietrich PY, Michielin O, Betticher D, Peters S

Rev Med Suisse. 2020 Apr 29;16(N° 691-2):819-822

Commentary to "Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials" (Galvano et al. J Bone Oncol 2019; 18:100252).

Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, Zaman K, Lamy O

J Bone Oncol. 2020 Jun;22:100294

LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma.

Keskin T, Bakaric A, Waszyk P, Boulay G, Torsello M, Cornaz-Buros S, Chevalier N, Geiser T, Martin P, Volorio A, Iyer S, Kulkarni A, Letovanec I, Cherix S, Cote GM, Choy E, Digklia A, Montemurro M, Chebib I, Nielsen PG, Carcaboso AM, Mora J, Renella R, Su

Cell Rep. 2020 Apr 14;31(2):107539

Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.

Delaloge S, Piccart M, Rutgers E, Litière S, van 't Veer LJ, van den Berkmortel F, Brain E, Dudek-Peric A, Gil-Gil M, Gomez P, Hilbers FS, Khalil Z, Knox S, Kuemmel S, Kunz G, Lesur A, Pierga JY, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Thompson AM,

J Clin Oncol. 2020 Apr 10;38(11):1186-1197

Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement.

Budczies J, Kazdal D, Allgäuer M, Christopoulos P, Rempel E, Pfarr N, Weichert W, Fröhling S, Thomas M, Peters S, Endris V, Schirmacher P, Stenzinger A

Lung Cancer. 2020 Apr;142:114-119

LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma LIN28B Control of EWS-FLI1 Stability.

Cell Rep. 2020 Mar 31;30(13):4567-4583.e5

Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study.

Pozzessere C, Bouchaab H, Jumeau R, Letovanec I, Daccord C, Bourhis J, Prior JO, Peters S, Lazor R, Beigelman-Aubry C

ERJ Open Res. 2020 Jan;6(1)

Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.

Molina-Vila MA, Stahel RA, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Curioni Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Ponce Aix S, Carcereny E, Früh M, Pless M, Popat S, Cuffe

J Thorac Oncol. 2020 Mar;15(3):416-425

Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?

Schmid S, Früh M, Peters S

Lancet Oncol. 2020 Mar;21(3):320-322

The isolation of cancer survivors.

Danesi G, Bourquin C, Stiefel F, Zaman K, Saraga M

Eur J Cancer Care (Engl). 2020 Mar;29(2):e13194

First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver.

Ponti A, Denys A, Digklia A, Schaefer N, Hocquelet A, Knebel JF, Michielin O, Dromain C, Duran R

J Nucl Med. 2020 Mar;61(3):350-356

Primary Sarcoma of the Lung - Prognostic Value of Clinicopathological Characteristics of 26 Cases.

Duran-Moreno J, Kokkali S, Ramfidis V, Salomidou M, Digklia A, Koumarianou A, Tomos P, Koufopoulos N, Vamvakaris I, Psychogiou E, Syrigos K

Anticancer Res. 2020 Mar;40(3):1697-1703

Journée du cancer : mobiliser autour de la prévention.

Peters S, Dietrich PY

Rev Med Suisse. 2020 Feb 19;16(682):382-383

Development and implementation strategies of a nurse-led symptom self-management program in outpatient cancer centres: The Symptom Navi© Programme.

Bana M, Ribi K, Kropf-Staub S, Näf E, Schramm MS, Zürcher-Florin S, Peters S, Eicher M

Eur J Oncol Nurs. 2020 Feb;44:101714

[Advances in Oncology 2019].

Vernadou A, Ferahta N, Mederos N, Ferraro D, Dischl-Antonioni I, Diciolla A, Liapi A, Mosimann V, Latifyan S, Aedo-Lopez V, Berthold D, Digklia A, Michielin O, Montemurro M, Wagner AD, Zaman K, Peters S, Stravodimou A, Sarivalasis A

Rev Med Suisse. 2020 Jan 15;16(676-7):72-77

Imaging of tumour response to immunotherapy.

Dromain C, Beigelman C, Pozzessere C, Duran R, Digklia A

Eur Radiol Exp. 2020 Jan 3;4(1):2

Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors.

Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, Zaman K, Lamy O

Breast Cancer Res Treat. 2020 Jan;179(1):153-159

Primary Care-Led Transition Clinics Hold Promise in Improving Care Transitions for Cancer Patients Facing Social Disparities: A Commentary.

Malebranche M, Sarivalasis A, Peters S, Mathevet P, Cornuz J, Bodenmann P

J Prim Care Community Health. 2020 Jan-Dec;11:2150132720957455

2019

Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.

Pillonel V, Dunet V, Hottinger AF, Berthod G, Schiappacasse L, Peters S, Michielin O, Aedo-Lopez V

J Immunother Cancer. 2019 Dec 2;7(1):336

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.

Pérol M, Pavlakis N, Levchenko E, Platania M, Oliveira J, Novello S, Chiari R, Moran T, Mitry E, Nüesch E, Liu T, Balas B, Konopa K, Peters S

Lung Cancer. 2019 Dec;138:79-87

Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report.

Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj-Levra M, Giaj-Levra N, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'Brien M, Reck M, Smit EF, Van Schil P, Postmus PE, Ramella S, Lievens Y, Gaga M, Peled N, Scagliotti GV,

J Thorac Oncol. 2019 Dec;14(12):2109-2119

Platelet and Neutrophil Counts as Predictive Markers of Neoadjuvant Therapy Efficacy in Rectal Cancer.

Policicchio A, Mercier J, Digklia A, Voutsadakis IA

J Gastrointest Cancer. 2019 Dec;50(4):894-900

A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.

Sarivalasis A, Boudousquié C, Balint K, Stevenson BJ, Gannon PO, Iancu EM, Rossier L, Martin Lluesma S, Mathevet P, Sempoux C, Coukos G, Dafni U, Harari A, Bassani-Sternberg M, Kandalaft LE

J Transl Med. 2019 Nov 26;17(1):391

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ,

N Engl J Med. 2019 Nov 21;381(21):2020-2031

Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.

Kazdal D, Endris V, Allgäuer M, Kriegsmann M, Leichsenring J, Volckmar AL, Harms A, Kirchner M, Kriegsmann K, Neumann O, Brandt R, Talla SB, Rempel E, Ploeger C, von Winterfeld M, Christopoulos P, Merino DM, Stewart M, Allen J, Bischoff H, Meister M, Mule

J Thorac Oncol. 2019 Nov;14(11):1935-1947

Synchronous tumors of the pancreas and the gallbladder: a case report with targeted NGS evaluation.

Sivade A, Sempoux C, Voutsadakis I, Brunel C, Halkic N, Godat S, Duran R, Digklia A

Ann Transl Med. 2019 Nov;7(22):696

Curative management of a cardiac metastasis from lung cancer revealed by an electrical storm.

Jumeau R, Vincenti MG, Pruvot E, Schwitter J, Vallet V, Zeverino M, Moeckli R, Bouchaab H, Bourhis J, Ozsahin M

Clin Transl Radiat Oncol. 2020 Mar;21:62-65

Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.

Cristina V, Herrera-Gómez RG, Szturz P, Espeli V, Siano M

Int J Mol Sci. 2019 Oct 30;20(21)

Appraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint Blockade.

Zimmermann S, Peters S

JAMA Oncol. 2019 Oct 1;5(10):1403-1405

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.

Schmid S, Klingbiel D, Aebi S, Goldhirsch A, Mamot C, Munzone E, Nolè F, Oehlschlegel C, Pagani O, Pestalozzi B, Rochlitz C, Thürlimann B, von Moos R, Weder P, Zaman K, Ruhstaller T

BMC Cancer. 2019 Sep 10;19(1):902

Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis.

Ascierto PA, Bifulco C, Palmieri G, Peters S, Sidiropoulos N

J Mol Diagn. 2019 Sep;21(5):756-767

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M

Nat Rev Clin Oncol. 2019 Sep;16(9):563-580

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patie

Bassani-Sternberg M, Digklia A, Huber F, Wagner D, Sempoux C, Stevenson BJ, Thierry AC, Michaux J, Pak H, Racle J, Boudousquie C, Balint K, Coukos G, Gfeller D, Martin Lluesma S, Harari A, Demartines N, Kandalaft LE

Front Immunol. 2019;10:1832

Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.

Dafni U, Tsourti Z, Vervita K, Peters S

Lung Cancer. 2019 Aug;134:127-140

(18)F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.

Jreige M, Letovanec I, Chaba K, Renaud S, Rusakiewicz S, Cristina V, Peters S, Krueger T, de Leval L, Kandalaft LE, Nicod-Lalonde M, Romero P, Prior JO, Coukos G, Schaefer N

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1859-1868

Implementation of the Symptom Navi © Programme for cancer patients in the Swiss outpatient setting: a study protocol for a cluster randomised pilot study (Symptom Navi© Pilot Study).

Bana M, Ribi K, Kropf-Staub S, Zürcher-Florin S, Näf E, Manser T, Bütikofer L, Rintelen F, Peters S, Eicher M

BMJ Open. 2019 Jul 9;9(7):e027942

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.

Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT

J Thorac Oncol. 2019 Jul;14(7):1233-1243

A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer.

Stravodimou A, Voutsadakis IA

Anticancer Res. 2019 Jul;39(7):3295-3301

Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice.

Szturz P, Cristina V, Herrera Gómez RG, Bourhis J, Simon C, Vermorken JB

Front Oncol. 2019;9:464

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).

Dziadziuszko R, Smit EF, Dafni U, Wolf J, Wasąg B, Biernat W, Finn SP, Kammler R, Tsourti Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E, Peters S

J Thorac Oncol. 2019 Jun;14(6):1086-1094

Solid cancer development in solid organ transplant recipients within the Swiss Transplant Cohort Study.

Lengwiler E, Stampf S, Zippelius A, Salati E, Zaman K, Schäfer N, Schardt J, Siano M, Hofbauer G, The Swiss Transplant Cohort Study

Swiss Med Wkly. 2019 May 6;149:w20078

[New therapeutic strategies in advanced stage breast and tubo-ovarian cancers].

Nikolopoulou A, Galli-Vareia I, Stravodimou A, Sarivalasis A, Zaman K

Rev Med Suisse. 2019 May 15;15(651):1027-1031

De sérieuses préoccupations qui ne cachent pas nos espoirs.

Aapro M, Peters S, Dietrich PY

Rev Med Suisse. 2019 May 15;15(651):999-1000

[The new management options for lung cancer in the immunotherapy era].

Meganem H, Socianu RM, Bouchaab H, Mederos N, Nguyen-Ngoc T, Peters S, Dolcan A

Rev Med Suisse. 2019 May 15;15(651):1032-1037

Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures.

Degrauwe N, Hocquelet A, Digklia A, Schaefer N, Denys A, Duran R

Front Pharmacol. 2019;10:450

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).

Curioni-Fontecedro A, Perentes JY, Gelpke H, Xyrafas A, Bouchaab H, Mach N, Matzinger O, Stojcheva N, Frueh M, Weder W, Cathomas R, Gargiulo P, Bubendorf L, Pless M, Betticher D, Peters S, Swiss Group of Clinical Cancer Research (SAKK)

Br J Cancer. 2019 May;120(10):968-974

A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.

Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Radonic T, Wilson J, De Luca G, Gray SG, Cheney R, Savic S, Martorell M, Mu

Lung Cancer. 2019 May;131:95-103

Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.

Martinez P, Peters S, Stammers T, Soria JC

Clin Cancer Res. 2019 May 1;25(9):2691-2698

Isodose 20 Gy found as a threshold dose for radiation recall dermatitis.

Scher N, Vozenin MC, Bouchaab H, Ozsahin M, Bourhis J

Clin Transl Radiat Oncol. 2019 Jul;17:14-16

Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.

Blackwell KL, Zaman K, Qin S, Tkaczuk KHR, Campone M, Hunt D, Bryce R, Goldstein LJ, 202 Study Group

Clin Breast Cancer. 2019 Apr;19(2):97-104.e4

Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre.

Jermini M, Dubois J, Rodondi PY, Zaman K, Buclin T, Csajka C, Orcurto A, E Rothuizen L

Sci Rep. 2019 Mar 25;9(1):5078

Intraductal patient-derived xenografts of estrogen receptor α-positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions.

Fiche M, Scabia V, Aouad P, Battista L, Treboux A, Stravodimou A, Zaman K, RLS, Dormoy V, Ayyanan A, Sflomos G, Brisken C

J Pathol. 2019 Mar;247(3):287-292

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.

Lai WV, Lebas L, Barnes TA, Milia J, Ni A, Gautschi O, Peters S, Ferrara R, Plodkowski AJ, Kavanagh J, Sabari JK, Clarke SJ, Pavlakis N, Drilon A, Rudin CM, Arcila ME, Leighl NB, Shepherd FA, Kris MG, Mazières J, Li BT

Eur J Cancer. 2019 Mar;109:28-35

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.

Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bow

Eur Urol Focus. 2019 Mar;5(2):242-249

50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.

Herrera FG, Valerio M, Berthold D, Tawadros T, Meuwly JY, Vallet V, Baumgartner P, Thierry AC, De Bari B, Jichlinski P, Kandalaft L, Coukos G, Harari A, Bourhis J

Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):320-334

Inappropriate Grading of Adverse Events in Cancer Clinical Trials-Reply.

Cristina V, Mauer M, Wagner AD

JAMA Oncol. 2019 Feb 1;5(2):269-270

Brain metastases.

Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, Peters S, Arvold ND, Harsh GR, Steeg PS, Chang SD

Nat Rev Dis Primers. 2019 Jan 17;5(1):5

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jas

J Clin Oncol. 2019 Jan 10;37(2):105-114

[Oncology, what's new in 2018].

Latifyan S, Kakourou A, Ozdemir B, Zaman K, Vernadou A, Berthold D, Abdelhamid K, Bouchaab H, Peters S, Montemurro M, Aedo V, Michielin O, Zimmermann S, Stravodimou A

Rev Med Suisse. 2019 Jan 9;15(N° 632-633):78-81

The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients.

Vozenin MC, De Fornel P, Petersson K, Favaudon V, Jaccard M, Germond JF, Petit B, Burki M, Ferrand G, Patin D, Bouchaab H, Ozsahin M, Bochud F, Bailat C, Devauchelle P, Bourhis J

Clin Cancer Res. 2019 Jan 1;25(1):35-42

Characterisation of rare haematological immune-related toxicities.

Haanen JB, Peters S

Lancet Haematol. 2019 Jan;6(1):e10-e11

Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01).

Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, Mirimanoff RO, Ochsenbein AF, Schmid R, Matzinger O, Stahel RA, Weder W, Guckenberger M, Rothschild SI, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Pless M, Swiss Grou

J Thorac Oncol. 2019 Jan;14(1):115-123

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.

Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, Baik CS, Isla D, Carpeno JC, Garrido P, Rittmeyer A, Tiseo M, Meyenberg C, de Haas S, Lam LH, Lu MW, Stinchcombe TE

Clin Cancer Res. 2019 Jan 1;25(1):64-72

Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach.

Nikolaou M, Nikolaou G, Digklia A, Pontas C, Tsoukalas N, Kyrgias G, Tolia M

Integr Cancer Ther. 2019 Jan-Dec;18:1534735419827090

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.

Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M

Lancet Oncol. 2019 Jan;20(1):e54-e64

2018

Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity.

Tsoutsou PG, Zaman K, Martin Lluesma S, Cagnon L, Kandalaft L, Vozenin MC

Front Oncol. 2018;8:609

Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.

Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J, Yu EY, Niegisch G, Vaishampayan UN, Theodore C, Berthold DR, Srinivas S, Sridhar SS, Plimack ER, Rosenberg JE, Powles T, Galsky MD, Necchi A

J Urol. 2018 Dec;200(6):1207-1214

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.

Peters S, Curioni-Fontecedro A, Nechushtan H, Shih JY, Liao WY, Gautschi O, Spataro V, Unk M, Yang JC, Lorence RM, Carrière P, Cseh A, Chang GC

J Thorac Oncol. 2018 Dec;13(12):1897-1905

Hepatocellular carcinoma abutting large vessels: comparison of four percutaneous ablation systems.

Loriaud A, Denys A, Seror O, Vietti Violi N, Digklia A, Duran R, Trillaud H, Hocquelet A

Int J Hyperthermia. 2018 Dec;34(8):1171-1178

Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.

Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaisham

Eur Urol Focus. 2018 Dec;4(6):937-945

Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort.

Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen LB, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S,

J Thorac Oncol. 2018 Dec;13(12):1851-1863

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.

Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes BG, Bouchaab H, Rothschild SI, Pavlakis N, Wolleb S, Petrausch U, O'Byrne K, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Sav

J Thorac Oncol. 2018 Nov;13(11):1784-1791

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C

J Clin Oncol. 2018 Oct 20;36(30):3007-3014

Effect of national HIV testing recommendations and local interventions on HIV testing practices in a Swiss university hospital: a retrospective analysis between 2012 and 2015.

Lazzarino T, Martenet S, Mamin R, Du Pasquier RA, Peters S, Perreau M, Muller O, Hugli O, Cavassini M, Darling KEA

BMJ Open. 2018 Oct 3;8(10):e021203

Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey.

Banerjee S, Dafni U, Allen T, Arnold D, Curigliano G MD, Garralda E, Garassino MC, Haanen J, Hofstädter-Thalmann E, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S

ESMO Open. 2018;3(6):e000422

Report on the status of women occupying leadership roles in oncology.

Hofstädter-Thalmann E, Dafni U, Allen T, Arnold D, Banerjee S, Curigliano G MD, Garralda E, Garassino MC, Haanen J, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S

ESMO Open. 2018;3(6):e000423

Acceptance of the Advanced Practice Nurse in Lung Cancer Role by Healthcare Professionals and Patients: A Qualitative Exploration.

Serena A, Dwyer AA, Peters S, Eicher M

J Nurs Scholarsh. 2018 Sep;50(5):540-548

Delineating the Role of PD-1/PD-L1 Blockade in Advanced SCLC.

Zimmermann S, Peters S

J Thorac Oncol. 2018 Sep;13(9):1242-1244

Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland.

Sandmeier N, Rothschild SI, Rothermundt C, Cathomas R, Schardt J, Berthold D, von Burg P, Müller B, Beyer J, Vogt DR, Stenner F

Clin Genitourin Cancer. 2018 Aug;16(4):e711-e718

Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group.

Cristina V, Mahachie J, Mauer M, Buclin T, Van Cutsem E, Roth A, Wagner AD

JAMA Oncol. 2018 Jul 1;4(7):1003-1006

Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.

Peters S, Zimmermann S

Curr Treat Options Oncol. 2018 May 28;19(7):37

Immune Checkpoint Inhibitors in the Management of Lung Cancer.

Zimmermann S, Peters S, Owinokoko T, Gadgeel SM

Am Soc Clin Oncol Educ Book. 2018 May 23;38:682-695

[High grade serous ovarian cancer 2018 : advances and controversies].

Mederos N, Wolfer A, Mathevet P, Zaher M, Sarivalasis A

Rev Med Suisse. 2018 May 16;14(607):1037-1041

[Liquid biopsy, a new opportunity for personalized oncology].

Astaras C, Dolcan A, Bisig B, Zaman K

Rev Med Suisse. 2018 May 16;14(607):1028-1032

De vrais espoirs et de sérieuses préoccupations.

Peters S, Dietrich PY, Aapro M

Rev Med Suisse. 2018 May 16;14(607):1011-1012

Genomic Features of Response to Combination Immunotherapy in Lung Cancer.

Früh M, Peters S

Cancer Cell. 2018 May 14;33(5):791-793

Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial.

Vietti Violi N, Duran R, Guiu B, Cercueil JP, Aubé C, Digklia A, Pache I, Deltenre P, Knebel JF, Denys A

Lancet Gastroenterol Hepatol. 2018 May;3(5):317-325

EML4-ALK Variant Affects ALK Resistance Mutations.

Früh M, Peters S

J Clin Oncol. 2018 Apr 20;36(12):1257-1259

Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.

Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Srinivas S, Berthold DR, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD, Retrospective International Study of Invasive/Adva

Clin Genitourin Cancer. 2018 Apr;16(2):e483-e490

[Sexuality after breast cancer is not a taboo].

Cairo Notari S, Fornage S, Panes-Ruedin B, Zaman K

Rev Med Suisse. 2018 Mar 14;14(598):563-565

RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma.

Faget J, Contat C, Zangger N, Peters S, Meylan E

J Thorac Oncol. 2018 Mar;13(3):387-398

Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.

Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Me

J Thorac Oncol. 2018 Mar;13(3):413-425

Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.

Costantini A, Grynovska M, Lucibello F, Moisés J, Pagès F, Tsao MS, Shepherd FA, Bouchaab H, Garassino M, Aerts JGJV, Mazières J, Mondini M, Berghmans T, Meert AP, Cadranel J

Eur Respir J. 2018 Feb;51(2)

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program.

Balmelli C, Railic N, Siano M, Feuerlein K, Cathomas R, Cristina V, Güthner C, Zimmermann S, Weidner S, Pless M, Stenner F, Rothschild SI

J Cancer. 2018;9(2):250-255

PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.

Peters S, Kerr KM, Stahel R

Cancer Treat Rev. 2018 Jan;62:39-49

2017

Questions about the formulation of erythropoietin mouthwash for the prevention of oral mucositis.

Fleury M, Shabafrouz K, Deplanque G

Hematol Oncol. 2017 Dec;35(4):931

[Local treatment in oligometastatic urological malignancies : evidence of wishful thinking ?].

Valerio M, Cerantola Y, Lucca I, Berthold D, Jichlinski P

Rev Med Suisse. 2017 Nov 29;13(585):2083-2086

Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer.

Rizvi NA, Peters S

N Engl J Med. 2017 Nov 16;377(20):1986-1988

Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.

Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E, Verbeken EK, Warth A, Sansano I, Cheney R, Speel EJM, Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger TR, Kammler R, Schulze

Lung Cancer. 2017 Sep;111:143-149

Iterative Reconstructions in Reduced-Dose CT: Which Type Ensures Diagnostic Image Quality in Young Oncology Patients?

Pauchard B, Higashigaito K, Lamri-Senouci A, Knebel JF, Berthold D, Verdun FR, Alkadhi H, Schmidt S

Acad Radiol. 2017 Sep;24(9):1114-1124

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, ALEX Trial Investigators

N Engl J Med. 2017 Aug 31;377(9):829-838

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, K

J Clin Oncol. 2017 Aug 20;35(24):2781-2789

Feasibility of advanced practice nursing in lung cancer consultations during early treatment: A phase II study.

Serena A, Dwyer A, Peters S, Eicher M

Eur J Oncol Nurs. 2017 Aug;29:106-114

Scientific Advances in Thoracic Oncology 2016.

Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist L

J Thorac Oncol. 2017 Aug;12(8):1183-1209

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bo

N Engl J Med. 2017 Jul 27;377(4):338-351

Patient and doctor perspectives on HIV screening in the emergency department: A prospective cross-sectional study.

De Rossi N, Dattner N, Cavassini M, Peters S, Hugli O, Darling KEA

PLoS One. 2017;12(7):e0180389

Can local radiotherapy and IL-12 synergise to overcome the immunosuppressive tumor microenvironment and allow "in situ tumor vaccination"?

Deplanque G, Shabafrouz K, Obeid M

Cancer Immunol Immunother. 2017 Jul;66(7):833-840

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Ha

N Engl J Med. 2017 Jun 22;376(25):2415-2426

Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program.

Papazoglou D, Wannesson L, Berthold D, Cathomas R, Gillessen S, Rothermundt C, Hasler L, Winterhalder R, Barth A, Mingrone W, Nussbaum CU, von Rohr L, von Burg P, Schmid M, Richner J, Baumann S, Kühne R, Stenner F, Rothschild SI

Clin Genitourin Cancer. 2017 Jun;15(3):e315-e323

[Treatment of advanced hepatocellular carcinoma : Novel agents and role of local therapy].

Parisod L, Duran R, Denys A, Digklia A

Rev Med Suisse. 2017 May 17;13(563):1032-1034

L’accès à l’innovation.

Aapro M, Dietrich PY, Peters S

Rev Med Suisse. 2017 May 17;13(563):1027

[Selective therapeutic de-escalation in early stage breast cancer].

Liapi A, Sarivalasis A, Jeanneret Sozzi W, Lelièvre L, Zaman K

Rev Med Suisse. 2017 May 17;13(563):1035-1038

[Head and neck cancer : promising results of immunotherapy].

Sivade A, Bensaid D, Monnier Y, Shabafrouz K, Bouchaab H, Cristina V

Rev Med Suisse. 2017 May 17;13(563):1029-1031

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M,

Lancet Respir Med. 2017 May;5(5):435-444

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.

Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF, Swiss Group for Clinical Cancer Research

Clin Lung Cancer. 2017 May;18(3):303-309

Minimizing adjuvant treatment after transoral robotic surgery through surgical margin revision and exclusion of radiographic extracapsular extension: A Prospective observational cohort study.

Morisod B, Venara-Vulpe II, Alzuphar S, Monnier Y, Bongiovanni M, Hagmann P, Bouchaab H, Bourhis J, Simon C

Head Neck. 2017 May;39(5):965-973

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic On

Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palme

J Thorac Oncol. 2017 Apr;12(4):752-762

A PET-based nomogram for oropharyngeal cancers.

Castelli J, Depeursinge A, Ndoh V, Prior JO, Ozsahin M, Devillers A, Bouchaab H, Chajon E, de Crevoisier R, Scher N, Jegoux F, Laguerre B, De Bari B, Bourhis J

Eur J Cancer. 2017 Apr;75:222-230

Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golsha

Eur Urol. 2017 Feb;71(2):281-289

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, va

J Thorac Oncol. 2017 Feb;12(2):194-207

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.

Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AMM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F

ESMO Open. 2016;1(6):e000142

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.

Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, Leighl N, Papotti M, Paz-Ares L, Pérol M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C

ESMO Open. 2016;1(6):e000118

2016

[Sarcoma centres : a necessary tool in the management of patients and for research.].

Cherix S, Vauclair F, Morattel B, Vautrin M, Matter M, Montemurro M, Digklia A, Letovanec I, Omoumi P, Saucy F, Gonzalez M, Durham AD, Bosisio F, Zyska Cherix AC, Rudiger HA

Rev Med Suisse. 2016 Dec 14;12(543):2172-2176

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V,

ESMO Open. 2016;1(6):e000107

[Common medications and prostate cancer : what is the association ?].

Rakauskas A, Grilo N, M'Baya O, Jichlinski P, Valerio M, Berthold D

Rev Med Suisse. 2016 Nov 30;12(541):2068-2071

[Subsolid pulmonary nodules].

Keller D, Beigelman-Aubry C, Letovanec I, Bouchaab H, Gonzalez M, Lovis A, Nicod LP, Lazor R

Rev Med Suisse. 2016 Nov 16;12(539):1976-1982

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III tr

Rochlitz C, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na KJ, Bärtschi D, Borner M, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R, Swiss Group for C

BMC Cancer. 2016 Oct 10;16(1):780

Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I.

Merz L, Zimmermann S, Peters S, Cavassini M, Darling KE

Oncologist. 2016 Oct;21(10):1176-1182

[Hormone therapy in invasive breast cancer : update 2016].

Zurcher JP, Stravodimou A, Zaman K

Rev Med Suisse. 2016 Sep 21;12(531):1580-1583

The cutting edge of metastatic melanoma therapy.

Digklia A, Michielin O

Melanoma Manag. 2016 Sep;3(3):217-229

[Curative treatment for esophageal cancer: results of a multidisciplinary consensus].

Allemann P, Mantziari S, Wagner D, Digklia A, Ozsahin E, De Bari B, Dorta G, Godat S, Montserrat F, Sempoux C, Brunel C, Demartines N, Schäfer M

Rev Med Suisse. 2016 Jun 15;12(523):1165-9

Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients.

De Bari B, Jumeau R, Bouchaab H, Vallet V, Matzinger O, Troussier I, Mirimanoff RO, Wagner AD, Hanhloser D, Bourhis J, Ozsahin EM

Acta Oncol. 2016 Jun;55(6):767-73

[BRCA mutations: from Angelina Jolie to specific therapies].

Lopez VA, Stravodimou A, Unger S, Perey L, Zaman K

Rev Med Suisse. 2016 May 18;12(519):973-4, 976-7

[Metastatic renal cell carcinoma, back to the future].

Martins F, Berthold D

Rev Med Suisse. 2016 May 18;12(519):994-8

Radiation Therapy after Radical Prostatectomy: Implications for Clinicians.

Herrera FG, Berthold DR

Front Oncol. 2016;6:117

Adjuvant ovarian function suppression and cognitive function in women with breast cancer.

Phillips KA, Regan MM, Ribi K, Francis PA, Puglisi F, Bellet M, Spazzapan S, Karlsson P, Budman DR, Zaman K, Abdi EA, Domchek SM, Feng Y, Price KN, Coates AS, Gelber RD, Maruff P, Boyle F, Forbes JF, Ahles T, Fleming GF, Bernhard J

Br J Cancer. 2016 Apr 26;114(9):956-64

The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer.

Peters S, Bexelius C, Munk V, Leighl N

Cancer Treat Rev. 2016 Apr;45:139-62

Advanced gastric cancer: Current treatment landscape and future perspectives.

Digklia A, Wagner AD

World J Gastroenterol. 2016 Feb 28;22(8):2403-14

Seeking New Approaches to Patients With Small Cell Lung Cancer.

Pietanza MC, Zimmerman S, Peters S, Curran WJ Jr

Am Soc Clin Oncol Educ Book. 2016;35:e477-82

The role of renal biopsy in small renal masses.

Burruni R, Lhermitte B, Cerantola Y, Tawadros T, Meuwly JY, Berthold D, Jichlinski P, Valerio M

Can Urol Assoc J. 2016 Jan-Feb;10(1-2):E28-33

2015

Multidisciplinary approach of lumbo-sacral chordoma: From oncological treatment to reconstructive surgery.

Garofalo F, di Summa PG, Christoforidis D, Pracht M, Laudato P, Cherix S, Bouchaab H, Raffoul W, Demartines N, Matter M

J Surg Oncol. 2015 Oct;112(5):544-54

BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.

Nguyen-Ngoc T, Bouchaab H, Adjei AA, Peters S

J Thorac Oncol. 2015 Oct;10(10):1396-403

Eribulin for heavily pre-treated metastatic breast cancer patients.

Digklia A, Voutsadakis IA

World J Exp Med. 2015 Aug 20;5(3):194-9

Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology.

Valdagni R, Van Poppel H, Aitchison M, Albers P, Berthold D, Bossi A, Brausi M, Denis L, Drudge-Coates L, De Santis M, Feick G, Harrison C, Haustermans K, Hollywood D, Hoyer M, Hummel H, Mason M, Mirone V, Müller SC, Parker C, Saghatchian M, Sternberg CN,

Crit Rev Oncol Hematol. 2015 Aug;95(2):133-43

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.

Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International

Cancer. 2015 Aug 1;121(15):2586-93

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.

Zaman K, Winterhalder R, Mamot C, Hasler-Strub U, Rochlitz C, Mueller A, Berset C, Wiliders H, Perey L, Rudolf CB, Hawle H, Rondeau S, Neven P

Eur J Cancer. 2015 Jul;51(10):1212-20

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?

Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, Kaufman B, Paluch-Shimon S, Gewefel H, Gallerani E, Abulkhair OM, Pistilli B, Warner E, Saloustros E, Perey L, Zaman K, Rabaglio M, Gelber S, Gelber RD, Goldhirsch A, Korde L, Azim HA Jr,

Breast. 2015 Jun;24(3):201-7

Stereotactic body radiotherapy with helical TomoTherapy for medically inoperable early stage primary and second-primary non-small-cell lung neoplasm: 1-year outcome and toxicity analysis.

Casutt A, Bouchaab H, Beigelman-Aubry C, Bourhis J, Lovis A, Matzinger O

Br J Radiol. 2015 May;88(1049):20140687

Angiogenic activity of breast cancer patients' monocytes reverted by combined use of systems modeling and experimental approaches.

Guex N, Crespo I, Bron S, Ifticene-Treboux A, Faes-Van't Hull E, Kharoubi S, Liechti R, Werffeli P, Ibberson M, Majo F, Nicolas M, Laurent J, Garg A, Zaman K, Lehr HA, Stevenson BJ, Rüegg C, Coukos G, Delaloye JF, Xenarios I, Doucey MA

PLoS Comput Biol. 2015 Mar;11(3):e1004050

Therapeutic drug monitoring of targeted anticancer therapy.

Decosterd LA, Widmer N, Zaman K, Cardoso E, Buclin T, Csajka C

Biomark Med. 2015;9(9):887-93

2014

Pulmonary sarcoid-like granulomatosis after multiple vaccinations of a long-term surviving patient with metastatic melanoma.

Bordry N, Costa-Nunes CM, Cagnon L, Gannon PO, Abed-Maillard S, Baumgaertner P, Murray T, Letovanec I, Lazor R, Bouchaab H, Rufer N, Romano E, Michielin O, Speiser DE

Cancer Immunol Res. 2014 Dec;2(12):1148-53

Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status.

Digklia A, Voutsadakis IA

World J Exp Med. 2014 Nov 20;4(4):58-67

Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer.

Digklia A, Voutsadakis IA

Obstet Gynecol Sci. 2014 Nov;57(6):457-63

Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.

Peters S, Bouchaab H, Zimmerman S, Bucher M, Gaide O, Letovanec I, Homicsko K, Michielin O

Melanoma Res. 2014 Oct;24(5):496-500

Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).

Templeton AJ, Ribi K, Surber C, Sun H, Hsu Schmitz SF, Beyeler M, Dietrich D, Borner M, Winkler A, Müller A, von Rohr L, Winterhalder RC, Rochlitz C, von Moos R, Zaman K, Thürlimann BJ, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK) Coordin

Breast. 2014 Jun;23(3):244-9

[Postoperative radiation therapy in lung carcinom].

Bouchaab H, Peters S, Ozsahin M, Peguret N, Gonzales M, Lovis A

Rev Med Suisse. 2014 May 21;10(431):1110-3

MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.

Romano E, Michielin O, Voelter V, Laurent J, Bichat H, Stravodimou A, Romero P, Speiser DE, Triebel F, Leyvraz S, Harari A

J Transl Med. 2014 Apr 12;12:97

Unusual presentation of cerebral venous sinus thrombosis associated with contraceptive usage.

Panos GD, Panos LD, Digklia A, Hafezi F, Gatzioufas Z

J Ophthalmic Vis Res. 2014 Apr;9(2):281-4

Cutaneous leukocytoclastic vasculitis associated with letrozole.

Digklia A, Tzika E, Voutsadakis IA

J Oncol Pharm Pract. 2014 Apr;20(2):146-8

Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology.

Dahmane E, Boccard J, Csajka C, Rudaz S, Décosterd L, Genin E, Duretz B, Bromirski M, Zaman K, Testa B, Rochat B

Anal Bioanal Chem. 2014 Apr;406(11):2627-40

Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.

Decensi A, Sun Z, Guerrieri-Gonzaga A, Thürlimann B, McIntosh C, Tondini C, Monnier A, Campone M, Debled M, Schönenberger A, Zaman K, Johansson H, Price KN, Gelber RD, Goldhirsch A, Coates AS, Aebi S

Breast Cancer Res Treat. 2014 Apr;144(2):321-9

Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series.

Stravodimou A, Zaman K, Voutsadakis IA

ISRN Oncol. 2014;2014:289836

Successes and limitations of targeted therapies in renal cell carcinoma.

Pracht M, Berthold D

Prog Tumor Res. 2014;41:98-112

2013

[Prostate cancer center: a multidisciplinary approach to accurately manage patients with prostate cancer].

Tawadros T, Burruni R, Herrera F, Codeluppi C, Zurkinden C, Meuwly JY, Lhermitte B, Berthold D

Rev Med Suisse. 2013 Dec 4;9(409):2270-2, 2274

Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss.

Zaman K, Thuerlimann B, Aebi S

J Clin Oncol. 2013 Sep 20;31(27):3440-1

High rate of completion of preventive therapy for latent tuberculosis infection among asylum seekers in a Swiss Canton.

Sarivalasis A, Bodenmann P, Langenskiold E, Lutchmaya-Flick C, Daher O, Zellweger JP

Swiss Med Wkly. 2013;143:w13860

The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond.

Jacot W, Fiche M, Zaman K, Wolfer A, Lamy PJ

Biochim Biophys Acta. 2013 Aug;1836(1):146-57

[Immunotherapy: a therapeutic revolution against prostate cancer?].

Pracht M, Herrera F, Tawadros T, Berthold D

Rev Med Suisse. 2013 May 22;9(387):1070-5

[Exemples of tumor markers and their clinical utility].

Sarivalasis A, Amram ML, Dietrich PY

Rev Med Suisse. 2013 May 22;9(387):1102-7

[Endocrine therapy in breast cancer: efficacy and adverse events].

Odermatt R, Wolfer A, Zaman K

Rev Med Suisse. 2013 May 22;9(387):1090-4

Targeted treatments for metastatic esophageal squamous cell cancer.

Digklia A, Voutsadakis IA

World J Gastrointest Oncol. 2013 May 15;5(5):88-96

Pretreatment thrombocytosis as a prognostic factor in metastatic breast cancer.

Stravodimou A, Voutsadakis IA

Int J Breast Cancer. 2013;2013:289563

Simultaneous renal oncocytoma and lymphoma: interest of lymphadenectomy.

Orcurto A, Lhermitte B, Sermier A, Berthold D

Case Rep Urol. 2013;2013:729108

2012

Factors associated with latent tuberculosis among asylum seekers in Switzerland: a cross-sectional study in Vaud County.

Sarivalasis A, Zellweger JP, Faouzi M, Daher O, Deslarzes C, Bodenmann P

BMC Infect Dis. 2012 Nov 2;12:285

Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).

Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D, Berthold DR, Pless M, Schiess R, von Moos R, Gillessen S, Swiss Group for Clinical Cancer Research SAKK

Clin Cancer Res. 2012 Nov 1;18(21):6049-57

Fertility preservation in cancer patients. Review of the French speaking part of Switzerland and recommendations for different situations.

Wunder D, Perey L, Réseau Romand Cancer et Fertilité, Achtari C, Ambrosetti A, Bellavia M, Delaloye JF, de Ziegler D, Gumy-Pause F, Helg C, Ketterer N, Petignat P, Primi MP, Rosselet-Christ A, Zaman K

Swiss Med Wkly. 2012;142:w13645

Relapsed seminoma during surveillance: first treatment choice should be radiotherapy.

Herrera F, Berthold DR

J Clin Oncol. 2012 Jun 1;30(16):2021; author reply 2022

[Breast cancer and obesity, a dangerous relation].

Zaman K, Bodmer A, Pralong F, Castiglione-Gertsch M

Rev Med Suisse. 2012 May 23;8(342):1101-4

Hand and foot syndrome associated with docetaxel treatment.

Stravodimou A, Voutsadakis IA

Acta Oncol. 2012 Apr;51(4):554-6

Definitive organ-sparing treatment of anal canal cancer: can we afford to question it?

Ozsahin M, Santa Cruz O, Bouchaab H, Matzinger O, Tsoutsou PG

J Clin Oncol. 2012 Feb 20;30(6):673-4; author reply 674-5

Peroxisome proliferator-activated receptor gamma and regulations by the ubiquitin-proteasome system in pancreatic cancer.

Stravodimou A, Mazzoccoli G, Voutsadakis IA

PPAR Res. 2012;2012:367450

Acute cerebrovascular accident after cisplatin treatment in a patient taking letrozole.

Digklia A, Voutsadakis IA

Chemotherapy. 2012;58(6):435-8

Severe peritonitis induced by methotrexate during treatment of persistent gestational trophoblastic disease.

Zimmermann S, Zaman K, Wolfer A, Jacot W

Oncologist. 2012;17(8):e18-20

2011

What makes a good pathology report?

Nobile A, Treboux A, Delaloye JF, Zaman K, Jeanneret-Sozzi W, Schaefer SC, Lehr HA

Eur J Cancer. 2011 Sep;47(14):2082-3

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, André S, Litière S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R, EORTC 10994/BIG 1-00 Study Investigat

Lancet Oncol. 2011 Jun;12(6):527-39

Proangiogenic factor PlGF programs CD11b(+) myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors.

Laurent J, Hull EF, Touvrey C, Kuonen F, Lan Q, Lorusso G, Doucey MA, Ciarloni L, Imaizumi N, Alghisi GC, Fagiani E, Zaman K, Stupp R, Shibuya M, Delaloye JF, Christofori G, Ruegg C

Cancer Res. 2011 Jun 1;71(11):3781-91

Breast sarcomas: current and future perspectives.

Voutsadakis IA, Zaman K, Leyvraz S

Breast. 2011 Jun;20(3):199-204

Pharmacotherapeutic management of locally advanced prostate cancer: current status.

Martin JM, Supiot S, Berthold DR

Drugs. 2011 May 28;71(8):1019-41

[Melanoma: a new therapeutic era].

Berthod G, Homicsko K, Bouchaab H, Matter M, Cerottini JP, Guggisberg D, Speiser D, Leyvraz S, Michielin O

Rev Med Suisse. 2011 May 25;7(296):1126-30

Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience.

Sturgeon JF, Moore MJ, Kakiashvili DM, Duran I, Anson-Cartwright LC, Berthold DR, Warde PR, Gospodarowicz MK, Alison RE, Liu J, Ma C, Pond GR, Jewett MA

Eur Urol. 2011 Apr;59(4):556-62

Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.

Homicsko K, Berthold DR

Anticancer Drugs. 2011 Jan;22 Suppl 1:S4-8

2010

[Cardiologic follow up of an oncologic patient].

Zaugg Longchamp D, Zaman K, Aebischer N

Rev Med Suisse. 2010 Jun 2;6(251):1133-4, 1136-9

[New drugs at the horizon for men with prostate cancer].

Shabafrouz K, Bauer J, Berthold DR

Rev Med Suisse. 2010 May 26;6(250):1057-8, 1060-1

Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial.

Azria D, Belkacemi Y, Romieu G, Gourgou S, Gutowski M, Zaman K, Moscardo CL, Lemanski C, Coelho M, Rosenstein B, Fenoglietto P, Crompton NE, Ozsahin M

Lancet Oncol. 2010 Mar;11(3):258-65